var title_f4_23_4464="EUS bile duct stone";
var content_f4_23_4464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choledocholithiasis seen on endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endosonographic image of a stone in the common bile duct with an acoustic shadow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Maryam Moini, MD, and Seyed Alireza Taghavi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4464=[""].join("\n");
var outline_f4_23_4464=null;
var title_f4_23_4465="Iron absorption model";
var content_f4_23_4465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Control of iron absorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this preliminary model, body iron status is sensed by duodenal crypt cells via an interaction between circulating transferrin-bound iron and the transferrin receptor (T, step 1), facilitated by a complex between the HFE protein (H) and beta 2-microglobulin (B). When body iron stores are sensed as \"low\" there is an upregulation of mRNA expression for the divalent metal transporter 1 (D, step 2). As the crypt cells migrate up the villus and mature into absorptive villus enterocytes, the amount of divalent metal transporter 1 protein is increased at the apical surface, facilitating iron absorption from the intestinal lumen (step 3). Absorbed iron is exported into the circulation via ferroportin (E, step 4), the activity of which is inhibited by hepcidin, an iron regulatory molecule produced in the liver and possibly influenced by the iron status of adjacent macrophages. This absorptive mechanism is disrupted in hereditary hemochromatosis when one or more genes in this pathway (eg, HFE, ferroportin, hepcidin) is mutated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4465=[""].join("\n");
var outline_f4_23_4465=null;
var title_f4_23_4466="Patient information: Cellulitis and erysipelas (skin infections) (The Basics)";
var content_f4_23_4466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/47/31473\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/4/22595\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/55/15217\">",
"         Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cellulitis-and-erysipelas-skin-infections-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1477091708\">",
"      <span class=\"h1\">",
"       What are cellulitis and erysipelas?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cellulitis and erysipelas are both infections of the skin. These infections can cause redness, pain, and swelling. The difference between them is that erysipelas tends to affect the upper layers of skin, and cellulitis tends to affect deep layers of skin and sometimes the fat under the skin.",
"     </p>",
"     <p>",
"      Cellulitis and erysipelas can happen when germs get into the skin. Normally, different types of germs live on a person&rsquo;s skin. Most of the time, these germs do not cause any problems. But if a person gets a cut or a break in the skin, the germs can get into the skin and cause an infection.",
"     </p>",
"     <p>",
"      Certain conditions can increase a person&rsquo;s chance of getting cellulitis or erysipelas. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having a cut (even a tiny one)",
"       </li>",
"       <li>",
"        Having another type of skin infection or a long-term skin condition",
"       </li>",
"       <li>",
"        Having swelling of the skin or swelling in the body",
"       </li>",
"       <li>",
"        Being overweight",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091715\">",
"      <span class=\"h1\">",
"       What are the symptoms of cellulitis and erysipelas?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Both types of infection cause very similar symptoms. Either infection can cause the infected area to be painful, red, swollen, or warm. Some people with cellulitis or erysipelas can sometimes also have fever or chills. And sometimes, people with these infections have no symptoms or only some of these symptoms.",
"     </p>",
"     <p>",
"      Most of the time, cellulitis and erysipelas happen on the legs or arms. But people can get these infections in other places, such as the belly, the face, in the mouth, or around the anus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091722\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do not need any tests. Your doctor or nurse will do an exam and look at your skin.",
"     </p>",
"     <p>",
"      It&rsquo;s important for a doctor or nurse to do an exam to figure out what kind of infection you have. The right treatment for a skin infection depends on the type of infection it is and which germs are causing it. Your doctor or nurse might need to do tests to figure out the cause of your infection.",
"     </p>",
"     <p>",
"      If you have cellulitis or erysipelas, it&rsquo;s important to get treated. These infections can spread to the whole body and become serious if not treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091729\">",
"      <span class=\"h1\">",
"       How are cellulitis and erysipelas treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These infections are treated with antibiotic pills. If your doctor prescribes medicine for you to take at home, it is important to follow the directions exactly. Take all of the pills you are given, even if you feel better before you finish them. If you do not take all the pills, the infection can come back worse.",
"     </p>",
"     <p>",
"      People who have severe infections might be treated in the hospital with antibiotics that go into the vein (called &ldquo;IV&rdquo;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091736\">",
"      <span class=\"h1\">",
"       What can I do to help treat my infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Raise your arm or leg (if your infection is on your arm or leg) to reduce swelling &ndash; Raise the arm or leg up above the level of your heart 3 or 4 times a day, for 30 minutes each time.",
"       </li>",
"       <li>",
"        Keep the infected area clean and dry &ndash; You can take a shower or bath, but be sure to pat the area dry with a towel afterward. Do not put any antibiotic ointments or creams on the area.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091743\">",
"      <span class=\"h1\">",
"       Should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call your doctor or nurse if your symptoms do not get better within 3 days of starting treatment. You should also call if the red area gets:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bigger",
"       </li>",
"       <li>",
"        More swollen",
"       </li>",
"       <li>",
"        More painful",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse might do another exam or tests to see if you need different medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091750\">",
"      <span class=\"h1\">",
"       Can skin infections be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. If you cut your skin, make sure to wash the area well with soap and water. This can help prevent the area from getting infected. If you have a long-term skin condition, ask your doctor or nurse what you can do to help prevent infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1477091757\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/47/31473?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=see_link\">",
"       Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/23/4466?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15728 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-115.25.216.6-56B6879C82-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4466=[""].join("\n");
var outline_f4_23_4466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091708\">",
"      What are cellulitis and erysipelas?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091715\">",
"      What are the symptoms of cellulitis and erysipelas?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091722\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091729\">",
"      How are cellulitis and erysipelas treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091736\">",
"      What can I do to help treat my infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091743\">",
"      Should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091750\">",
"      Can skin infections be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1477091757\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/47/31473?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=related_link\">",
"      Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_23_4467="Pseudoaneurysm of the splenic artery";
var content_f4_23_4467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoaneurysm of the splenic artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pseudoaneurysm of the splenic artery seen on contrast enhanced CT scan showing outline of contained pseudoaneurysm (arrows) and internal contrast blush (star).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas J Howard, MD, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4467=[""].join("\n");
var outline_f4_23_4467=null;
var title_f4_23_4468="Risks and benefits of alcohol";
var content_f4_23_4468=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Risks and benefits of alcohol (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/23/4468/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4468/contributors\" id=\"au4466\">",
"       Kenneth J Mukamal, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/23/4468/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4468/contributors\" id=\"se323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/23/4468/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4468/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?4/23/4468?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Is alcohol good for your health?",
"    </p>",
"    <p>",
"     For many reasons, this is a question without simple or clear-cut answers. Humans have used alcohol safely and enjoyably for thousands of years, and it continues to occupy an important place in many religious ceremonies and social celebrations. In addition, moderate alcohol use can provide certain health benefits, particularly with regard to coronary heart disease.",
"    </p>",
"    <p>",
"     However, alcohol consumption is also associated with serious risks. Drinking too much alcohol contributes to accidents and injuries and can lead to liver disease, certain types of stroke, high blood pressure, various cancers, and birth defects, among other health problems. Thus, understanding the possible risks and benefits of alcohol is essential to make an informed decision about alcohol use.",
"    </p>",
"    <p>",
"     Alcohol abuse is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=see_link\">",
"      \"Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW MUCH IS ONE DRINK?",
"     </span>",
"    </p>",
"    <p>",
"     Alcoholic drinks come in multiple forms and contain differing amounts of pure alcohol (ethanol); in the United States, one portion of alcohol is defined as approximately 10 to 15 grams of ethanol, which can be found in:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       One 12 ounce bottle or can of beer (roughly equivalent to the 330 mL cans of beers sold in some countries)",
"      </li>",
"      <li>",
"       One 5 ounce serving of wine (about 150 mL)",
"      </li>",
"      <li>",
"       One shot (1.5 ounces) of 80-proof distilled spirits (about 50 mL)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In general, studies that evaluate the health effects of alcohol designate different drinking patterns (eg, heavy, moderate, or light drinking) based upon the number of drinks consumed per day or week. Moderate drinking is generally defined as 3 to 9 servings of alcohol per week.",
"    </p>",
"    <p>",
"     Internationally, there is a broad range of what defines a &ldquo;standard drink,&rdquo; ranging from 8 grams in the United Kingdom to 19.75 grams in Japan [",
"     <a class=\"abstract\" href=\"UTD.htm?4/23/4468/abstract/1\">",
"      1",
"     </a>",
"     ]. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HEALTH CONDITIONS AND ALCOHOL",
"     </span>",
"    </p>",
"    <p>",
"     Multiple studies suggest that consuming alcohol can affect the risk of developing certain health conditions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Cardiovascular disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cardiovascular disease, including disorders of the heart, blood vessels, and blood circulation, is the leading cause of death in the United States. However, several studies suggest that moderate alcohol use, as compared to heavy drinking or abstaining, decreases the risk of coronary heart disease (CHD) and the most common type of stroke (ischemic stroke) by 25 to 40 percent.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      High blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who consume more than two drinks per day have up to a twofold increase in the incidence of high blood pressure compared with nondrinkers. However, the effect of drinking less than two drinks per day on high blood pressure remains unclear. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Heart attack",
"     </span>",
"     &nbsp;&mdash;&nbsp;Drinking a moderate amount of alcohol is associated with lower risk of having a heart attack. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"      \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Peripheral vascular disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Peripheral vascular disease can cause pain in the calves with walking, also known as claudication. Moderate alcohol use reduces the risk of peripheral artery disease in healthy men. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"      \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Stroke",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol consumption has been shown to affect the risk of stroke in contradictory ways, depending upon the amount of alcohol consumed and the type of stroke. A stroke occurs when brain tissue dies as a result of a sudden, severe disruption of blood flow and insufficient oxygen. Strokes may be due to a blockage (ischemic stroke) or rupture and leakage (hemorrhagic stroke) of one of the blood vessels supplying the brain.",
"    </p>",
"    <p>",
"     Heavy alcohol use increases the risk of both ischemic and hemorrhagic stroke. Moderate alcohol use is associated with fewer ischemic strokes; the risk appears to be lowest in people who consume one drink or less per day. In contrast, the risk of hemorrhagic stroke appears to rise even with minimal alcohol use.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Breast cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is consistent evidence that breast cancer risk is higher for women consuming moderate to high levels of alcohol (three or more",
"     <span class=\"nowrap\">",
"      drinks/day)",
"     </span>",
"     compared with abstainers. Drinking as little as one to two drinks per day also appears to increase this risk. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"      \"Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Taking folic acid (folate) may reduce the effect of alcohol consumption on breast cancer, suggesting that women who drink alcohol may benefit from a daily multivitamin fortified with folic acid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cancers of the head and neck and digestive tract",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol use has been linked to several types of cancer of the head and neck and digestive (gastrointestinal) tract, even at low levels of consumption. People who drink and smoke have a greater risk than would be expected from either factor alone.",
"    </p>",
"    <p>",
"     Cancer arising within liver cells (hepatocellular carcinoma) has been linked to alcohol use. This may be related to liver scarring (ie, cirrhosis) that occurs in people who consume excessive amounts of alcohol since cirrhosis is a major cause of hepatocellular carcinoma. Low levels of alcohol do not clearly cause cirrhosis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      \"Patient information: Cirrhosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, even at low levels, drinking may increase the risk of hepatocellular cancer in people with inflammation of the liver (hepatitis) due to infection with certain viruses (ie, hepatitis C virus). People with chronic hepatitis should avoid alcohol. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      \"Patient information: Hepatitis C (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Cirrhosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low levels of alcohol do not clearly cause cirrhosis. Heavy drinking (at least five drinks daily) is generally required to cause cirrhosis in men.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Gallstones",
"     </span>",
"     &nbsp;&mdash;&nbsp;Moderate alcohol use has been shown to lower the risk of gallstones. However, heavy drinking may reverse this benefit. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"      \"Patient information: Gallstones (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Pancreatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heavy drinking increases the risk of both sudden (acute) and long-term (chronic) inflammation of the pancreas (pancreatitis). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"      \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/45/26322?source=see_link\">",
"      \"Patient information: Chronic pancreatitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Osteoporosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heavy drinking increases the risk of hip fractures because it increases the risk of both osteoporosis and falls.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is a significant risk of birth defects related to use of alcohol use during pregnancy. Heavy drinking can cause fetal alcohol syndrome, which prevents normal growth, and may cause intellectual disability (mental retardation), malformations of the skull and face, and other findings.",
"    </p>",
"    <p>",
"     Moderate alcohol consumption may also be harmful, although this is a matter of some controversy. There is no known benefit of alcohol use during pregnancy. Thus, experts advise completely avoiding alcohol during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Perception of health and quality of life",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excessive and frequent alcohol use reduces quality of life for individuals, their families, and others around them, potentially leading to failure at work or school, interpersonal problems, and physically hazardous situations.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Accidents and trauma",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol use increases the risks and severity of injury from motor vehicle accidents.",
"    </p>",
"    <p>",
"     Exposure to alcohol is generally measured in blood alcohol concentration (BAC) rather than drinks per day or week. In most of the United States, the legal BAC limit for driving is 0.08 percent, which corresponds to about 4 drinks for a 200 pound man and 2.5 drinks for a 150 pound woman. However, the risk of having an accident while driving doubles at a BAC of only 0.05 percent, and driving ability is impaired with BACs as low as 0.02 percent.",
"    </p>",
"    <p>",
"     Alcohol also increases the risk of injury from other sources. It has been shown to impair a pilot's ability to fly and an operator's ability to control a boat, bicycle, and snowmobile. In addition, occupational injuries, falls, drownings, burns, and hypothermia are more common in those who use alcohol, particularly in heavy drinkers. Alcohol is involved in more than one-quarter of all rapes, at least one-half of serious assaults, and one-half to two-thirds of all homicides.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Suicide",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol abuse is associated with an increased risk of suicide. However, moderate drinking does not appear to raise suicide risk.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      IS ALCOHOL SAFE FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     The bottom line is that it is difficult to weigh the benefits and risks of alcohol. Nevertheless, several important conclusions can be drawn:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Beginning to drink alcohol may be inappropriate for people who have been lifelong abstainers. There is no evidence that abstainers who begin drinking will lower their risk of any disease.",
"      </li>",
"      <li>",
"       The diseases that may be prevented by moderate drinking (eg, coronary heart disease and ischemic stroke) are most prevalent in older adults, men, and people with CHD risk factors (eg, hypertension, hypercholesterolemia, smoking, diabetes mellitus). For these groups, moderate alcohol use may substantially reduce the risk of dying.",
"      </li>",
"      <li>",
"       For young to middle-aged adults, particularly women, moderate alcohol use increases the risk of the most common causes of death, such as breast cancer and trauma. Men under age 45 years also may experience more harm than benefit from drinking. In these younger age groups, moderate alcohol use is unlikely to reduce the risk of dying.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Consuming less than one drink daily appears to be safe (that is, if not done before or while operating a car or heavy equipment), although even that level of drinking can be dangerous for some people (see next section).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Reasons to avoid alcohol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol use is not recommended for individuals who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Are younger than the legal drinking age (21 years in most states within the United States)",
"      </li>",
"      <li>",
"       Are pregnant",
"      </li>",
"      <li>",
"       Have a personal or strong family history of alcoholism",
"      </li>",
"      <li>",
"       Have a personal or strong family history of breast cancer",
"      </li>",
"      <li>",
"       Have had hemorrhagic stroke",
"      </li>",
"      <li>",
"       Have liver or pancreatic disease",
"      </li>",
"      <li>",
"       Have precancerous conditions of the digestive tract",
"      </li>",
"      <li>",
"       Operate potentially dangerous equipment or machinery (including cars, boats, planes, or construction equipment)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Wine versus other alcoholic beverages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some research suggests that wine provides the strongest protection against cardiovascular disease, possibly due to naturally occurring compounds known as flavonoids. In France, for example, death from CHD is lower than would be expected from the high rate of smoking and saturated fats in the diet; this \"French paradox\" has been attributed to frequent red wine consumption.",
"    </p>",
"    <p>",
"     However, other studies indicate that all alcoholic beverages offer cardioprotective benefits. Whether beverage type matters for specific diseases other than CHD remains uncertain, although most evidence suggests that it does not.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      An \"ideal dose\" of alcohol",
"     </span>",
"     &nbsp;&mdash;&nbsp;As mentioned above, for some people,",
"     <strong>",
"      no amount of alcohol",
"     </strong>",
"     is considered safe. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Reasons to avoid alcohol'",
"     </a>",
"     above.) However, for individuals without such conditions, the healthiest dose of alcohol appears to be in the range of 0.5 to 1 drink of alcohol daily.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Gender differences",
"     </span>",
"     &nbsp;&mdash;&nbsp;Established recommendations for safe levels of drinking do not address an \"ideal\" level of alcohol consumption. However, they advise",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       No more than two drinks daily for men",
"      </li>",
"      <li>",
"       No more than one drink daily for women",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      What is the best approach in my case?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following guidelines may help in making an informed decision about alcohol use:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Consult a healthcare provider to determine the specific risks and benefits of alcohol use. Multiple factors must be considered in any such \"risk-benefit analysis,\" including age, sex, personal medical history, family history, diet, physical fitness, and certain lifestyle choices such as smoking, among others.",
"      </li>",
"      <li>",
"       If drinking alcohol is appropriate, follow recommended guidelines concerning moderate drinking, ie, limiting intake to no more than one drink daily for women or two drinks daily for men.",
"      </li>",
"      <li>",
"       Women should not drink any alcohol during pregnancy; in addition, experts advise that women should stop drinking when trying to conceive.",
"      </li>",
"      <li>",
"       Never consume alcohol before or while driving or operating any potentially dangerous equipment.",
"      </li>",
"      <li>",
"       Speak with your child's doctor about preventing alcohol use and abuse in children and teenagers. Unfortunately, Americans are commonly introduced to alcohol during adolescence, around the same time that they are introduced to automobiles; this can be a deadly combination.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Adults should model responsible drinking for children and adolescents by either abstaining from alcohol or drinking in moderation. Clearly, children exposed to alcohol abuse in their parents are more likely to become alcoholic themselves.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498523377\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H431949\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37137?source=see_link\">",
"      Patient information: Alcohol poisoning (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/3/44081?source=see_link\">",
"      Patient information: Alcohol withdrawal (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=see_link\">",
"      Patient information: Marijuana use and addiction (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/40/38529?source=see_link\">",
"      Patient information: Fetal alcohol syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/39/31346?source=see_link\">",
"      Patient information: Cocaine use disorder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/46/17122?source=see_link\">",
"      Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H431964\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=see_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/45/26322?source=see_link\">",
"      Patient information: Chronic pancreatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9496?source=see_link\">",
"      Hepatitis C and alcohol",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15577?source=see_link\">",
"      Identification and management of alcohol use disorders in the perioperative period",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaaa.nih.gov/\">",
"      www.niaaa.nih.gov",
"     </a>",
"     and",
"     <a class=\"external\" href=\"file://www.collegedrinkingprevention.gov/\">",
"      www.collegedrinkingprevention.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Family Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.familydoctor.org/\">",
"      www.familydoctor.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.health.org/\">",
"      www.health.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?4/23/4468/abstract/2-4\">",
"      2-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 1, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?4/23/4468?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     International Center for Alcohol Policies; International drinking guidelines, 2003. file://www.icap.org/LinkClick.aspx?fileticket=KtXj8PGibT8%3D&amp;tabid=75 (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4468/abstract/2\">",
"      Pearson TA, Terry P. What to advise patients about drinking alcohol. The clinician's conundrum. JAMA 1994; 272:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4468/abstract/3\">",
"      Zhang SM, Lee IM, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007; 165:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4468/abstract/4\">",
"      Leon DA, Saburova L, Tomkins S, et al. Hazardous alcohol drinking and premature mortality in Russia: a population based case-control study. Lancet 2007; 369:2001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f4_23_4468=[""].join("\n");
var outline_f4_23_4468=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW MUCH IS ONE DRINK?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HEALTH CONDITIONS AND ALCOHOL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           IS ALCOHOL SAFE FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f4_23_4469="EMG neurogenic and myopathic";
var content_f4_23_4469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Electromyography*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1. At rest (spontaneous activity): a. fibrilations, b. positive sharp waves, c. fasiculation.",
"    <br>",
"     2. Slight effort (motor unit potentials): d. giant polyphasic, e. BSAPS (brief-small-abundant polyphasic).",
"     <br>",
"      3. Strong effort (interference pattern): f. full, g. reduced units, h. reduced amplitude.",
"      <div class=\"footnotes\">",
"       * (helpful in selecting denervated muscles [in radiculopathies (myotomal), mononeuropathies (distal to lesion), generalized neuropathies (distal muscles)] and myopathies)",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4469=[""].join("\n");
var outline_f4_23_4469=null;
var title_f4_23_4470="Flutamide: Drug information";
var content_f4_23_4470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flutamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/53/12117?source=see_link\">",
"    see \"Flutamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flutamide&reg;;",
"     </li>",
"     <li>",
"      Euflex&reg;;",
"     </li>",
"     <li>",
"      Eulexin&reg;;",
"     </li>",
"     <li>",
"      Novo-Flutamide;",
"     </li>",
"     <li>",
"      PMS-Flutamide;",
"     </li>",
"     <li>",
"      Teva-Flutamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate carcinoma:",
"     </b>",
"     Oral: 250 mg 3 times/day; alternatively, once-daily doses of 0.5-1.5 g have been used (unlabeled dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female hirsutism (unlabeled use):",
"     </b>",
"     Oral: 250 mg daily (Moghetti, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary in patients with chronic renal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use is contraindicated in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 125 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F173228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually administered orally in 3 divided doses. Contents of capsule may be opened and mixed with applesauce, pudding, or other soft foods. Mixing with a beverage is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic prostatic carcinoma in combination therapy with LHRH agonist analogues",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F173284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Female hirsutism",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flutamide may be confused with Flumadine&reg;, thalidomide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Eulexin&reg; may be confused with Edecrin&reg;, Eurax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hot flashes, breast tenderness, galactorrhea (9% to 42%), impotence, libido decreased, tumor flare",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (transient; mild), LDH increased (transient; mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (1%), edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, confusion, depression, anxiety, nervousness, headache, dizziness, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Ecchymosis, photosensitivity, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite increased, constipation, indigestion, upset stomach (4% to 6%); diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (6%), leukopenia (3%), thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes zoster",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hepatic failure, hepatitis, hypersensitivity pneumonitis, jaundice, malignant breast neoplasm (male), MI, pulmonary embolism, sulfhemoglobinemia, thrombophlebitis, yellow discoloration of the urine",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flutamide or any component of the formulation; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic failure:",
"     <b>",
"      [U.S. Boxed Warning]: Hospitalization and, rarely, death due to liver failure have been reported in patients taking flutamide.",
"     </b>",
"     Elevated serum transaminase levels, jaundice, hepatic encephalopathy, and acute hepatic failure have been reported. In some patients, the toxicity reverses after discontinuation of therapy. About 50% of the cases occur within the first 3 months of treatment. Serum transaminase levels should be measured prior to starting treatment, monthly for 4 months, and periodically thereafter. Liver function tests should be obtained at the first suggestion of liver dysfunction (nausea, vomiting, abdominal pain, fatigue, anorexia, &ldquo;flu-like&rdquo; symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness). Should be immediately discontinued any time a patient has jaundice, and/or an ALT level greater than twice the upper limit of normal. Should not be used in patients whose ALT values are greater than twice the upper limit of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemoglobin M disease: Patients with hemoglobin M disease are at risk of toxicities associated with aniline exposure, including methemoglobinemia, hemolytic anemia, and cholestatic jaundice; monitor methemoglobin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6 phosphate dehydrogenase deficiency: Patients with glucose-6 phosphate dehydrogenase deficiency are at risk of toxicities associated with aniline exposure, including methemoglobinemia, hemolytic anemia, and cholestatic jaundice; monitor methemoglobin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Patients who smoke are at risk of toxicities associated with aniline exposure, including methemoglobinemia, hemolytic anemia, and cholestatic jaundice; monitor methemoglobin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: Product labeling states it is not for use in women, particularly for non-life-threatening conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F173241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: No effect on bioavailability of flutamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease flutamide levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Adverse events have been observed in animal reproduction studies. When used for the treatment of hirsutism, adequate contraception is recommended throughout therapy and for 3 months after therapy is complete (Falsetti, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F173233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Flutamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (180): $376.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F173222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum transaminase levels should be measured prior to starting treatment and should be repeated monthly for the first 4 months of therapy, and periodically thereafter. LFTs should be checked at the first sign or symptom of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness). Other parameters include tumor reduction, testosterone/estrogen, prostate specific antigen, and phosphatase serum levels.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F173234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bedozane (LU);",
"     </li>",
"     <li>",
"      Cytomid-250 (IN);",
"     </li>",
"     <li>",
"      Drogenil (GB, IE);",
"     </li>",
"     <li>",
"      Etaconil (CN, PE);",
"     </li>",
"     <li>",
"      Eulexin (AE, AR, AU, BE, BH, BR, CR, CY, DO, EG, FI, GT, HN, IR, IT, KE, KP, KW, LU, LY, MX, NI, NL, NO, NZ, OM, PA, PK, PT, QA, SA, SE, SV, SY, TR, VE);",
"     </li>",
"     <li>",
"      Eulexine (FR);",
"     </li>",
"     <li>",
"      Eumide (MY);",
"     </li>",
"     <li>",
"      Flucinom (CH, CZ, GR);",
"     </li>",
"     <li>",
"      Flucinome (HR);",
"     </li>",
"     <li>",
"      Flugerel (PL, TW);",
"     </li>",
"     <li>",
"      Fluken (MX);",
"     </li>",
"     <li>",
"      Flulem (CO, MX, TH);",
"     </li>",
"     <li>",
"      Flumid (SG);",
"     </li>",
"     <li>",
"      Fluta-Cell (ID);",
"     </li>",
"     <li>",
"      Flutacan (LU);",
"     </li>",
"     <li>",
"      Flutam (HU);",
"     </li>",
"     <li>",
"      Flutamex (DE);",
"     </li>",
"     <li>",
"      Flutamid (RU);",
"     </li>",
"     <li>",
"      Flutamid Abbott (HU);",
"     </li>",
"     <li>",
"      Flutamin (AU, NZ);",
"     </li>",
"     <li>",
"      Flutan (SG, TH);",
"     </li>",
"     <li>",
"      Flutanon (PH);",
"     </li>",
"     <li>",
"      Flutaplex (CO, ID, TH);",
"     </li>",
"     <li>",
"      Flutasin (BG);",
"     </li>",
"     <li>",
"      Flutax (AR);",
"     </li>",
"     <li>",
"      Flutrax (EC);",
"     </li>",
"     <li>",
"      Fluxus (EC, PY);",
"     </li>",
"     <li>",
"      Fugerel (AT, AU, HK, HU, PH, TH);",
"     </li>",
"     <li>",
"      Fuprostatel (TW);",
"     </li>",
"     <li>",
"      Profamid (DK);",
"     </li>",
"     <li>",
"      Prostacur (ES);",
"     </li>",
"     <li>",
"      Prostica (DE);",
"     </li>",
"     <li>",
"      Tafenil (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F173212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonsteroidal antiandrogen that inhibits androgen uptake or inhibits binding of androgen in target tissues",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Parent drug: 94% to 96%; 2-hydroxyflutamide: 92% to 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to more than 10 metabolites, primarily 2-hydroxyflutamide (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-6 hours (2-hydroxyflutamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Airhart RA, Barnett TF, Sullivan JW, &ldquo;Flutamide Therapy for Carcinoma of the Prostate,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1978, 71(7):798-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/78529/pubmed\" id=\"78529\" target=\"_blank\">",
"        78529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Azziz R, &ldquo;The Evaluation and Management of Hirsutism,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2003, 101(5 Pt 1):995-1007.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/12738163/pubmed\" id=\"12738163\" target=\"_blank\">",
"        12738163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN and Chrisp P, &ldquo;Flutamide. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Advanced Prostatic Cancer,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1991, 1(2):104-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/1794008/pubmed\" id=\"1794008\" target=\"_blank\">",
"        1794008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN and Clissold SP, &ldquo;Flutamide. A Preliminary Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1989, 38(2):185-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/2670515/pubmed\" id=\"2670515\" target=\"_blank\">",
"        2670515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delaere KP and Van Thillo EL, &ldquo;Flutamide Monotherapy as Primary Treatment in Advanced Prostatic Carcinoma,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1991, 18(5 Suppl 6):13-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/1948117/pubmed\" id=\"1948117\" target=\"_blank\">",
"        1948117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falsetti L, Gambera A, Platto C, et al, \"Management of Hirsutism,\"",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2000, 1(2):89-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/11702316/pubmed\" id=\"11702316\" target=\"_blank\">",
"        11702316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldspiel BR and Kohler DR, &ldquo;Flutamide: An Antiandrogen for Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       DICP Ann Pharmacother",
"      </i>",
"      , 1990, 24(6):616-23.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunter MH and Carek PJ, &ldquo;Evaluation and Treatment of Women With Hirsutism,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 2003, 67(12):2565-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/12825846/pubmed\" id=\"12825846\" target=\"_blank\">",
"        12825846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kassem NY, Nero RO, and Munroe JS, &ldquo;Effect of Flutamide, An Antiandrogen, on Stage D Cancer of the Prostate,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1981, 29:256.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Labrie F, &ldquo;Mechanism of Action and Pure Antiandrogenic Properties of Flutamide,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1993, 72(12 Suppl):3816-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/8252497/pubmed\" id=\"8252497\" target=\"_blank\">",
"        8252497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luo S, Martel C, Chen C, &ldquo;Daily Dosing With Flutamide or Casodex Exerts Maximal Antiandrogenic Activity,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 1997, 50(6):913-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/9426723/pubmed\" id=\"9426723\" target=\"_blank\">",
"        9426723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al, \"Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(4):1105-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/18252793/pubmed\" id=\"18252793\" target=\"_blank\">",
"        18252793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghetti P, Tosi F, Tosti A, et al, &ldquo;Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2000, 85(1):89-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/10634370/pubmed\" id=\"10634370\" target=\"_blank\">",
"        10634370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thrasher JB, Deeths J, and Bennett C, &ldquo;Comparative Study of the Clinical Efficacy of Two Dosing Regimens of Flutamide,&rdquo;",
"      <i>",
"       Mol Urol",
"      </i>",
"      , 2000, 4(3):259-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/23/4470/abstract-text/11062382/pubmed\" id=\"11062382\" target=\"_blank\">",
"        11062382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8471 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4470=[""].join("\n");
var outline_f4_23_4470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708803\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173245\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173288\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173249\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173250\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896259\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896260\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173224\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173209\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173228\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173227\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173284\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173296\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173286\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173231\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173213\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173281\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173218\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173241\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173233\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173222\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173234\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173212\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173230\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/53/12117?source=related_link\">",
"      Flutamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_23_4471="Genetic code";
var content_f4_23_4471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Genetic code",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    amber: stop codon UGA (U replacing T in RNA)",
"    <br>",
"     ochre: stop codon UAA (U replacing T in RNA)",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4471=[""].join("\n");
var outline_f4_23_4471=null;
var title_f4_23_4472="Management of fingertip injuries";
var content_f4_23_4472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of fingertip injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Richard A Saladino, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Peter Antevy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4472/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/23/4472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17719229\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail bed injuries and fingertip avulsions occur frequently and may have significant associated functional or cosmetic morbidity. These injuries are commonly treated in an outpatient setting. Nail bed lacerations require careful repair and measures to preserve the nail folds and germinal matrix. Complete fingertip avulsions require debridement, cleansing, and local wound care.",
"   </p>",
"   <p>",
"    The repair of nail bed lacerations and fingertip avulsions are reviewed here. The management of subungual hematoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link\">",
"     \"Subungual hematoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1958511\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated nail bed injury typically occurs as a result of direct blunt trauma (eg, crush in a door jamb). A nail bed injury almost always accompanies a partial or complete fingertip avulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Fingertip avulsions often occur in the setting of door closure upon the finger, either along the edge of the door on the side of the hinge or the latch. Most avulsions are partial avulsions of the fingertip, although full amputations are not rare.",
"   </p>",
"   <p>",
"    Fingertip avulsions are also caused by knives, slicers, exercise equipment (eg, treadmills, exercise bicycles), power tools and lawn mowers. In contrast to adults, complete or partial avulsions heal extremely well in children especially before adolescence. In particular, the literature indicates that children younger than two years of age are very likely to demonstrate complete distal tip regeneration after amputation when managed without repair [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17719243\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper management of fingertip injuries requires knowledge of anatomy of the nail bed as well as familiarity with the motor and neurovascular anatomy of the finger (",
"    <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"     figure 1",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nail bed is a thin layer of epithelial tissue overlying the cortex of the distal phalanx.",
"     </li>",
"     <li>",
"      The skin that covers the proximal end is called the proximal fold or eponychium.",
"     </li>",
"     <li>",
"      The skin edge at the distal nail margin is called the hyponychium.",
"     </li>",
"     <li>",
"      The lateral margins of the nail are held in place by the lateral skin folds of the fingertip.",
"     </li>",
"     <li>",
"      The richly vascularized nail bed lies directly beneath the nail plate and provides adherence and support for the nail.",
"     </li>",
"     <li>",
"      The cuticle, an outgrowth of the proximal fold, provides a seal between the proximal fold and the nail plate.",
"     </li>",
"     <li>",
"      The germinal matrix is the proximal element of the nail bed responsible for most of the nail formation. The matrix begins 7 to 8 mm under the proximal fold, and its distal end is the white crescent called the lunula.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The fingertip has a rich blood supply provided by numerous branches of the ulnar and radial elements of the digital arteries. The pad of the fingertip is composed of fatty and soft tissues with dense sensory innervation provided by the palmar digital nerves. Extension and flexion of the fingertip are provided by the extensor hood tendons and flexor digitorum profundus, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link&amp;anchor=H6#H6\">",
"     \"Finger and thumb anatomy\", section on 'Finger extension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link&amp;anchor=H7#H7\">",
"     \"Finger and thumb anatomy\", section on 'Finger flexion and pulley system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2001263\">",
"    <span class=\"h1\">",
"     INDICATIONS, CONTRAINDICATIONS, AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should perform primary repair of nail bed injuries that are uninfected and less than 24 hours old. The nail must be removed completely for adequate examination and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Complete fingertip avulsions require debridement and cleansing regardless of when the injury occurred. Small nail bed lacerations in which the nail is solidly intact within the nail folds do not require nail removal and repair. If a painful subungual hematoma is present in such patients, then trephination should be performed instead. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link&amp;anchor=H13#H13\">",
"     \"Subungual hematoma\", section on 'Nail trephination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1959144\">",
"    <span class=\"h2\">",
"     Indications for subspecialty consultation or referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following injuries warrant consultation with a hand surgeon, if available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infected wounds",
"     </li>",
"     <li>",
"      Fingertip injuries with associated tendon injuries",
"     </li>",
"     <li>",
"      Finger fractures (other than tuft fractures) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H7#H7\">",
"       \"Distal phalanx fractures\", section on 'Indications for surgical referral'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complicated digit dislocations (eg, open dislocation) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link&amp;anchor=H10#H10\">",
"       \"Digit dislocation reduction\", section on 'Contraindications and precautions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Large soft tissue injuries (&gt;1 cm) in children with absent, destroyed, or heavily contaminated tissues requiring nail bed or skin grafting",
"     </li>",
"     <li>",
"      Extensive proximal germinal matrix avulsion",
"     </li>",
"     <li>",
"      Extensive laceration that extends beneath the proximal fold (eponychium) that will require exposure and repair of the germinal matrix",
"     </li>",
"     <li>",
"      Amputations with significant bone exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17719257\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452522\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper management of nail bed lacerations and fingertip avulsions requires careful evaluation, including assessment for associated injuries and plain radiographs, prior to definitive care. This assessment should identify conditions that warrant prompt referral to a hand or orthopedic surgeon. (See",
"    <a class=\"local\" href=\"#H2001263\">",
"     'Indications, contraindications, and precautions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       History",
"      </strong>",
"      &ndash; Key historical elements include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age and skeletal maturity",
"     </li>",
"     <li>",
"      Mechanism and time of injury",
"     </li>",
"     <li>",
"      Digit position during injury (flexed versus extended)",
"     </li>",
"     <li>",
"      Dominant hand",
"     </li>",
"     <li>",
"      Occupation",
"     </li>",
"     <li>",
"      Prior hand conditions, injuries, or interventions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physical examination",
"      </strong>",
"      &ndash; The clinician should determine the extent of damage to the nail, nail folds, nail bed, and germinal matrix by inspection and evaluate for associated proximal injuries to the finger or hand by testing neurovascular status and range of motion.",
"      <br/>",
"      <br/>",
"      Findings of nail bed laceration include subungual hematoma, bleeding from under the nail and disruption or dislocation of the nail plate.",
"      <br/>",
"      <br/>",
"      Vascular compromise is suggested by the presence of distal pallor. The vascular status of fingers is also evaluated using capillary refill time. Although standard values for capillary refill time increase with age and certain disease states (eg, diabetes), normal capillary refill is generally less than two seconds [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/9\">",
"       9",
"      </a>",
"      ]. Comparison of capillary refill time with an unaffected finger assists with interpretation.",
"      <br/>",
"      <br/>",
"      Two-point discrimination is the most sensitive test for sensation in the fingers. In cooperative patients, a paper clip opened and bent into a caliper with the points at 10 mm is commonly used. The patient is asked to close his or her eyes, and the paper clip points are placed against the skin along the long axis of the finger. The touch should be relatively light so as to minimize the stimulation of pressure receptors. It is important to assess sensation on both the radial and ulnar aspects of the finger as well as the dorsal and palmar sides. The points of the paper clip are gradually brought closer together; two point discrimination of 4 to 5 mm is normal for most patients, with an upper limit of normal of 8 to 9 mm in elderly patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H79#H79\">",
"       \"The detailed neurologic examination in adults\", section on 'Two-point discrimination'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In cooperative younger children, it may only be possible to test light touch. A cotton tipped swab touched lightly on all aspects of the finger may suffice for this examination. Finally, in very young or uncooperative children, the clinician may not be able to discern the presence or absence of nerve injury. Indirect evidence of intact sensory innervation is obtained by placing the finger in a bowl of warm water for five minutes. Intact innervation is indicated by wrinkling of the skin of the distal finger, whereas nerve injury results in persistence of smooth skin.",
"      <br/>",
"      <br/>",
"      The detailed evaluation of range of motion of the finger and detection of fractures and dislocations is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link&amp;anchor=H12#H12\">",
"       \"Digit dislocation reduction\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H5#H5\">",
"       \"Distal phalanx fractures\", section on 'Symptoms and physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Plain radiographs",
"      </strong>",
"      &ndash; AP and true lateral plain radiographs are necessary before repair of a nail bed laceration or fingertip amputation to exclude associated fractures and to assist in identifying complex dislocations or fractures that warrant referral to a hand surgeon. Distal tuft fractures are the most common associated injuries seen with fingertip avulsions, occurring in up to 50 percent of injuries and do not significantly alter their immediate management, although the presence of a tuft fracture warrants splinting of the fingertip [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452530\">",
"    <span class=\"h2\">",
"     Patient counseling and informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fingertip injuries are usually anxious and in pain. The patient and, for children, the caretaker should receive an explanation of the injury and the procedural approach. In patients with significant nail bed lacerations and suspected damage to the area near the germinal matrix, the patient and family should be advised that a deformed or absent nail may occur on the finger despite appropriate treatment. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452538\">",
"    <span class=\"h2\">",
"     Local anesthesia, analgesia, and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate analgesia, local anesthesia, and, especially in children, distraction by a child life specialist or other personnel, may help to decrease the anxiety and pain of the procedure and promote successful repair. A digital block often provides adequate analgesia in older adolescents and adults, and in most children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link&amp;anchor=H12#H12\">",
"     \"Digital nerve block\", section on 'Digital block procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parenteral analgesia (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    typical maximum single dose: 10 mg) may be required infrequently. In younger or uncooperative children, procedural sedation may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2002221\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be assembled:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digital tourniquet (",
"      <a class=\"graphic graphic_picture graphicRef71108 \" href=\"UTD.htm?10/23/10623\">",
"       picture 1",
"      </a>",
"      ), Penrose drain, or finger of a sterile glove (Penrose drain or glove finger require a hemostat to hold in place)",
"     </li>",
"     <li>",
"      Irrigation solution (eg, sterile normal saline)",
"     </li>",
"     <li>",
"      Large volume (eg, 50 or 60 mL) Luer tip syringe with 19 gauge needle or irrigation device with splash shield (eg, Zerowet&reg;)",
"     </li>",
"     <li>",
"      Suture tray with, at minimum, needle driver, fine surgical (iris) scissors, and forceps",
"     </li>",
"     <li>",
"      Sterile paper or cloth drapes",
"     </li>",
"     <li>",
"      Absorbable suture (eg, 5-0, 6-0 chromic gut) for nail bed repair",
"     </li>",
"     <li>",
"      Absorbable suture (eg, 4-0, 5-0 chromic gut suture,",
"      <strong>",
"       not",
"      </strong>",
"      fast-absorbing gut) for suturing of skin and for holding the nail plate in place, alternatively skin glue",
"      <strong>",
"       ma",
"      </strong>",
"      y be used to hold nail in place.",
"     </li>",
"     <li>",
"      No. 15 scalpel blade",
"     </li>",
"     <li>",
"      Vasoline impregnated gauze",
"     </li>",
"     <li>",
"      Sterile gauze",
"     </li>",
"     <li>",
"      Finger splint",
"     </li>",
"     <li>",
"      Magnifying eyewear (optional)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452546\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330664\">",
"    <span class=\"h2\">",
"     Fingertip skin avulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin of the fingertip may be avulsed by being pinched in a metal door or cut off by a knife or other sharp implement (eg, box cutter). The resulting injury often leaves a circular wound on the distal fingertip with exposure of the subcutaneous tissue. The approach to this wound depends upon the specific injury as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial fingertip skin avulsion &ndash; These injuries may be repaired with absorbable suture (eg, 5-0 chromic) using simple interrupted stitches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"       \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Full fingertip skin avulsion &ndash; The approach to these injuries is determined by the size of the defect, whether the amputated tissue is available, and the age of the patient:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Defect &lt;1 cm &ndash; allow the injury to granulate or, if available, suture the cleaned and defatted amputated tissue in place with absorbable suture (eg, 5-0 chromic) and simple interrupted stitches (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"       \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Defect &gt;1 cm &ndash; if the amputated tissue is available, clean and defat it and then suture it in place with absorbable suture (eg, 5-0 chromic) using simple interrupted stitches (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"       \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      If the amputated tissue is not available, but the patient is under two years of age, the wound may simply be dressed and allowed to granulate. Patients over two years of age warrant prompt consultation with or referral within 24 hours to a hand surgeon for possible grafting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17719301\">",
"    <span class=\"h2\">",
"     Nail bed injury and repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for nail bed repair is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/1,6-8,10\">",
"     1,6-8,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to repair and after assessing neurovascular status as above, perform a digital block.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link&amp;anchor=H12#H12\">",
"       \"Digital nerve block\", section on 'Digital block procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While waiting for the block to take effect, have the patient soak the fingertip in a dilute solution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      and normal saline.",
"     </li>",
"     <li>",
"      Place a digital tourniquet (",
"      <a class=\"graphic graphic_picture graphicRef71108 \" href=\"UTD.htm?10/23/10623\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Remove the fingernail to fully expose the nail bed by gently separating the underlying adherent nail bed from the nail using fine-tipped (iris) scissors or small, curved hemostat (eg, Mosquito hemostat) as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hold the tip parallel to the finger and angled slightly dorsally towards the nail.",
"     </li>",
"     <li>",
"      Insert the scissors or hemostat in a closed position between the nail and nail bed at the distal tip and advance the instrument slowly in the proximal direction. Open and spread the instrument while maintaining the tips against the nail to avoid further injury to the nail bed.",
"     </li>",
"     <li>",
"      Repeat this process along several tracts until the nail is completely freed from the underlying nail bed, proximal fold, and lateral folds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Once the nail is removed, the nail bed should be gently irrigated with at least 100 to 200 mL of sterile saline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carefully approximate and suture the wound where it intersects the proximal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lateral folds using 5-0 chromic gut (",
"      <a class=\"graphic graphic_picture graphicRef78692 \" href=\"UTD.htm?15/9/15504\">",
"       picture 2",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Close the wound on the skin of the finger pad using 5-0 absorbable suture (eg, Ethilon&reg;).",
"     </li>",
"     <li>",
"      Repair the nail bed using absorbable suture (eg, 6-0 chromic) as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Align the edges of the nail bed precisely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct the needle from distal to proximal when passing the suture needle to avoid tearing the nail bed tissue and use the minimum number of sutures necessary to achieve adequate approximation (",
"      <a class=\"graphic graphic_picture graphicRef61915 \" href=\"UTD.htm?40/0/40974\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Protect the repaired nail bed by splinting with the original nail, if possible:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gently clean the nail in a dilute solution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      and normal saline.",
"     </li>",
"     <li>",
"      Place a large hole, 3 to 4 mm in diameter, in the center of the nail using a sterile needle, scalpel, or electrocautery to allow drainage.",
"     </li>",
"     <li>",
"      Replace the nail beneath the proximal fold (",
"      <a class=\"graphic graphic_picture graphicRef72699 \" href=\"UTD.htm?2/55/2931\">",
"       picture 4",
"      </a>",
"      ) and suture it in place through the lateral skin folds with two 4.0 chromic sutures. Alternatively, secure the nail in position using a tissue adhesive (eg, Dermabond&reg;) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the original nail cannot be used, place a nonadherent splint consisting of a single thickness of nonadherent sterile gauze (eg, Telfa&reg; gauze), 0.20 inch reinforced silicon sheeting, or sterile foil from the suture packet in the proximal fold and suture in place through the lateral skin folds using absorbable 4-0 suture or use skin glue (",
"      <a class=\"graphic graphic_picture graphicRef86803 \" href=\"UTD.htm?26/13/26836\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply a protective dressing consisting of a layer of Vasoline-impregnanted gauze (eg, Xeroform&reg;) covered with sterile dry gauze and a finger splint. Splinting options include a four pronged distal finger splint, a finger splint that is placed around the end of the finger for dorsal and volar protection, or a volar finger splint. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H18#H18\">",
"       \"Splinting of musculoskeletal injuries\", section on 'Finger splints'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Remove the tourniquet",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1959042\">",
"    <span class=\"h2\">",
"     Partial fingertip avulsion or amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial fingertip avulsions with an intact skin bridge may survive, provided some distal perfusion is preserved, especially in children younger than two years of age. At worst, the tip acts as a graft that may revascularize or act as a biologic dressing in older children, adolescents, and healthy adults. In adults with increased infectious risk due to comorbidities (eg, peripheral artery disease, diabetes mellitus, advanced age), removal of the avulsed fingertip and treatment as for complete fingertip amputation may be advisable. (See",
"    <a class=\"local\" href=\"#H1959050\">",
"     'Complete fingertip avulsions or amputations'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Management of partial fingertip avulsions or amputation is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/7,8,10\">",
"     7,8,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to repair and after careful neurovascular exam, perform a digital block.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link&amp;anchor=H12#H12\">",
"       \"Digital nerve block\", section on 'Digital block procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While waiting for the block to take effect, have the patient soak the fingertip in a dilute solution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      and normal saline.",
"     </li>",
"     <li>",
"      Place a digital tourniquet (",
"      <a class=\"graphic graphic_picture graphicRef71108 \" href=\"UTD.htm?10/23/10623\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Carefully remove the fingernail to fully expose the nail bed by gently separating the underlying adherent nail bed from the nail using fine-tipped scissors or a small, curved hemostat (eg, mosquito hemostat) as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hold the tip parallel to the finger and angled slightly dorsally towards the nail.",
"     </li>",
"     <li>",
"      Insert the scissors or hemostat in a closed position between the nail and nail bed at the distal tip and advance the instrument slowly in the proximal direction. Open the instrument while maintaining the tips against the nail to avoid further injury to the nail bed.",
"     </li>",
"     <li>",
"      Repeat this process along several tracts until the nail is completely freed from the underlying nail bed, proximal fold, and lateral folds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Once the nail is removed, the wound should be gently irrigated with at least 100 to 200 mL of sterile saline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Secure the avulsed fingertip in anatomic position with 4-0 absorbable suture (eg, chromic gut using the proximal and lateral folds as anatomic landmarks). The first sutures should be placed where the wound margin intersects with the lateral fold or lateral border of the proximal fold.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repair the skin laceration along the volar aspect of the fingertip using 5-0 chromic gut. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"       \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repair the nail bed and proceed as described in the previous section. (See",
"      <a class=\"local\" href=\"#H17719301\">",
"       'Nail bed injury and repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1959050\">",
"    <span class=\"h2\">",
"     Complete fingertip avulsions or amputations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of age, wounds involving complete avulsion or amputation of the fingertip limited to the distal skin and pulp are best managed with thorough irrigation, minimal debridement of devitalized tissues and application of a nonadherent sterile dressing (eg, Vasoline-impregnated gauze [Xeroform&reg; or Adaptic&reg;] covered with sterile dry gauze and a distal splint). Complete soft tissue avulsions or amputations can have fairly good results in young children under two to three years of age when the tip is cleaned, defatted and reapproximated as described for partial fingertip avulsions above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/13\">",
"     13",
"    </a>",
"    ]. Discussion with a hand surgeon is warranted for such injuries in older patients if the clinician is uncertain about the best approach. &nbsp;",
"   </p>",
"   <p>",
"    Complete amputations of the fingertip involving no or minimal exposed distal phalangeal bone are best managed by wound irrigation, debridement, and application of a nonadherent sterile dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Exposed bone need not be shortened unless extensive soft tissue loss has occurred or the patient is older than 12 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/10\">",
"     10",
"    </a>",
"    ]. Such patients should receive prompt consultation from a hand surgeon, if available. (See",
"    <a class=\"local\" href=\"#H1959144\">",
"     'Indications for subspecialty consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2278833\">",
"    <span class=\"h1\">",
"     ADDITIONAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28679206\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that healthy patients with clean or minimally contaminated fingertip injuries",
"    <strong>",
"     not",
"    </strong>",
"    receive empiric antibiotics. This recommendation is based upon the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An unblinded trial of 146 children under 18 years of age with fingertip injuries found no significant difference in infection rates among those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      or no antibiotic after repair (6 versus 3 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/14\">",
"       14",
"      </a>",
"      ]. None of the 52 patients with associated tuft fractures developed infections, including 22 patients who also received no antibiotics.",
"     </li>",
"     <li>",
"      A blinded trial of 193 adults with open distal phalanx fractures, including nail bed injuries and fingertip avulsions or amputations, demonstrated no significant difference in infection rates between those who received flucloxacillin and placebo (3 and 4 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with several other studies in healthy patients that demonstrate no reduction in infection risk following wound repair when prophylactic antibiotics are used, including patients with simple hand lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Some experts advocate prophylactic antibiotics in patients with excessive wound contamination (eg, soil contamination), vascular insufficiency (eg, devascularized wound, peripheral artery disease), or immunocompromise, although little evidence exists to support this practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H38#H38\">",
"     \"Closure of skin wounds with sutures\", section on 'Prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic antibiotics reduce the rate of infection due to some animal bites, especially cat bites. Although routine antibiotic prophylaxis is not recommended for all bite wounds, prophylaxis is warranted for bite wounds to the hand, including fingertip injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link&amp;anchor=H8#H8\">",
"     \"Soft tissue infections due to dog and cat bites\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H7#H7\">",
"     \"Soft tissue infections due to human bites\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28679222\">",
"    <span class=\"h2\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should determine the patient's tetanus vaccination status and provide prophylaxis if indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H10#H10\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link&amp;anchor=H11#H11\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2278519\">",
"    <span class=\"h2\">",
"     Wound care and patient instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient and, in children, the caretaker should be advised to leave the dressing and, if applicable, the finger splint in place until the follow-up visit. If the bandage should become wet or soiled prior to this visit, the patient should urgently return to have the wound redressed. Pain management consists of elevation of the hand above the heart and oral nonsteroidal antiinflammatory medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ). Oral opioid medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ) are also necessary for patients with extensive injury. Patients and caretakers should understand that blood may continue to ooze under the nail for one to two days. Excessive soiling of the dressing, hemorrhage, fever, redness extending up the finger, or marked dorsal hand swelling are indications for emergent reevaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2278841\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further follow-up and care are based upon the type of injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fingertip skin avulsions",
"      </strong>",
"      &ndash; Small defects (&lt;1 cm) and sutured injuries warrant follow-up with the primary care provider for a wound check in two to three days. If the wound is sutured, the patient or caregiver should be advised at that visit that the sutured skin will likely not survive but that it will serve as a biological dressing and eventually slough off. Continued home care consists of keeping the wound clean and dry and daily to every other day dressing changes. Additional wound checks are at the discretion of the provider. A typical approach is to evaluate the wound again in approximately two weeks when healing should be well established.",
"      <br/>",
"      <br/>",
"      Grafted defects should undergo follow-up as determined by the hand surgeon.",
"     </li>",
"     <li>",
"      <strong>",
"       Nail bed repair and sutured partial fingertip avulsions or amputations",
"      </strong>",
"      &ndash; The patient should follow-up with a hand surgeon in five to seven days. The bandage should remain intact until the initial visit with the hand surgeon. Thereafter, the timing of dressing changes and additional wound checks should be frequent enough to observe for problems with healing or infection but spaced such that disruption of wound and nail bed revascularization is minimized and may vary according to the degree of injury. Weekly wound checks are a common approach among hand surgeons. Some specialists advise every other day dressing changes while others prefer to only perform dressing changes as part of the wound check. &nbsp;",
"      <br/>",
"      <br/>",
"      Patients and caretakers should understand that the sutured nail is acting only to maintain patency of the proximal fold by preventing adhesions between the eponychium and nail bed and that it will fall off within one to three weeks. Ultimately, a new nail will require 3 to 12 months to grow in again [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If a tuft fracture is present, then finger splinting should continue for at least 14 days.",
"     </li>",
"     <li>",
"      <strong>",
"       Complete amputations &ndash;",
"      </strong>",
"      These injuries warrant follow-up with a hand surgeon in five to seven days. The bandage should remain intact until the initial visit with the hand surgeon. After the initial visit, these wounds should undergo regular dressing changes as determined by the hand surgeon. Regular evaluation is advised until healing is complete.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1958641\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications consist of abnormality of nail growth and wound infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal nail growth &ndash; Normal nail growth following a nail bed laceration requires a smooth nail bed. Extensive injury or failure to precisely approximate the nail bed may result in an irregular contour of or a nonadherent nail [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/6-8,10,20\">",
"       6-8,10,20",
"      </a>",
"      ]. Scarring of the germinal matrix may result in failure of nail regrowth or an abnormally formed fingernail (eg, hypoplastic nail). Scarring of the nail bed results in a nail that fails to adhere to the underlying nail bed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/7,8,20\">",
"       7,8,20",
"      </a>",
"      ]. Scar tissue formation may also result in a hyperaesthetic nail bed and fingertip [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/8\">",
"       8",
"      </a>",
"      ]. Scarring of the proximal (eponychial) fold may yield a split nail or pain as the nail grows through the adhesion [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/7\">",
"       7",
"      </a>",
"      ]. Lateral fold scarring may result in ingrown nails [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Meticulous repair of the nail bed with careful approximation of the nail folds, minimal debridement of the nail bed, and use of the minimum number of sutures to adequately close the nail bed wound serve to minimize these undesirable cosmetic outcomes.",
"     </li>",
"     <li>",
"      Wound infection &ndash; The reported infection rate after hand and fingertip injuries is approximately 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4472/abstract/14,21\">",
"       14,21",
"      </a>",
"      ]. Careful wound debridement and irrigation are most important in preventing this complication. Prophylactic antibiotics do not significantly alter the rate of infection in healthy patients with minimally contaminated wounds. (See",
"      <a class=\"local\" href=\"#H28679206\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17719381\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingertip avulsions often occur in the setting of door closure upon the finger. A nail bed injury almost always accompanies a full or partial fingertip avulsion. Fingertip avulsions are also caused by knives, slicers, exercise equipment (eg, treadmills, exercise bicycles), power tools and lawn mowers. (See",
"      <a class=\"local\" href=\"#H1958511\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper management of fingertip injuries requires knowledge of the anatomy of the nail bed (",
"      <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17719243\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt consultation with a hand surgeon is warranted for infected wounds; fingertip injuries with associated tendon injuries; displaced finger fractures (other than tuft fractures); complicated digit dislocations (eg, open dislocation); large soft tissue injuries (&gt;1 cm) in children with absent, destroyed, or heavily contaminated tissues requiring nail bed or skin grafting; large proximal germinal matrix avulsion or laceration; or amputations with significant bone exposure. (See",
"      <a class=\"local\" href=\"#H1959144\">",
"       'Indications for subspecialty consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to local anesthesia and treatment, patients should undergo neurovascular assessment of the finger and plain radiographs. (See",
"      <a class=\"local\" href=\"#H452522\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A digital block often provides adequate analgesia for treatment in older adolescents and adults and in most children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link&amp;anchor=H12#H12\">",
"       \"Digital nerve block\", section on 'Digital block procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of fingertip injuries is provided. (See",
"      <a class=\"local\" href=\"#H2002221\">",
"       'Materials'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H452546\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that healthy patients with clean or minimally contaminated fingertip injuries",
"      <strong>",
"       not",
"      </strong>",
"      receive empiric antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Some experts advocate prophylactic antibiotics in patients with excessive wound contamination (eg, soil contamination), vascular insufficiency (eg, devascularized wound, peripheral artery disease), or immunocompromise, although little evidence exists to support this practice. (See",
"      <a class=\"local\" href=\"#H28679206\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should determine the patient's tetanus vaccination status and provide prophylaxis, if indicated (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28679222\">",
"       'Tetanus prophylaxis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The patient should be referred to a hand surgeon or other clinician with similar expertise for a wound check two to three days after initial treatment. (See",
"      <a class=\"local\" href=\"#H2278519\">",
"       'Wound care and patient instructions'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Antevy, PM, Saladino, RA. Management of finger injuries. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King, C, Henretig, FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.939.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/2\">",
"      Ljungberg EM, Carlsson KS, Dahlin LB. Cost per case or total cost? The potential of prevention of hand injuries in young children - retrospective and prospective studies. BMC Pediatr 2008; 8:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/3\">",
"      de Alwis W. Fingertip injuries. Emerg Med Australas 2006; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/4\">",
"      Rosenthal LJ, Reiner MA, Bleicher MA. Nonoperative management of distal fingertip amputations in children. Pediatrics 1979; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/5\">",
"      Zook EG, Guy RJ, Russell RC. A study of nail bed injuries: causes, treatment, and prognosis. J Hand Surg Am 1984; 9:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/6\">",
"      Van Beek AL, Kassan MA, Adson MH, Dale V. Management of acute fingernail injuries. Hand Clin 1990; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/7\">",
"      Roberts, J. Fingernail avulsion and injury to the nail bed. Emerg Med News  1993; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/8\">",
"      Shepard GH. Management of acute nail bed avulsions. Hand Clin 1990; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/9\">",
"      Schriger DL, Baraff L. Defining normal capillary refill: variation with age, sex, and temperature. Ann Emerg Med 1988; 17:932.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts, J, Hedges, J. Clinical Procedures in Emergency Medicine, 4th, WB Saunders, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/11\">",
"      Richards AM, Crick A, Cole RP. A novel method of securing the nail following nail bed repair. Plast Reconstr Surg 1999; 103:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/12\">",
"      Strauss EJ, Weil WM, Jordan C, Paksima N. A prospective, randomized, controlled trial of 2-octylcyanoacrylate versus suture repair for nail bed injuries. J Hand Surg Am 2008; 33:250.",
"     </a>",
"    </li>",
"    <li>",
"     Sommer, NZ, Brown, RE. The perionychium. In: Green's Operative Hand Surgery, Volume 1, 6th edition, Wolfe, SW, Hotchkiss, RN, Pederson, WC, Kozin, SH (Eds), Elsevier Churchill Livingstone, Philadelphia 2011. p.333.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/14\">",
"      Altergott C, Garcia FJ, Nager AL. Pediatric fingertip injuries: do prophylactic antibiotics alter infection rates? Pediatr Emerg Care 2008; 24:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/15\">",
"      Stevenson J, McNaughton G, Riley J. The use of prophylactic flucloxacillin in treatment of open fractures of the distal phalanx within an accident and emergency department: a double-blind randomized placebo-controlled trial. J Hand Surg Br 2003; 28:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/16\">",
"      Grossman JA, Adams JP, Kunec J. Prophylactic antibiotics in simple hand lacerations. JAMA 1981; 245:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/17\">",
"      Roberts AH, Teddy PJ. A prospective trial of prophylactic antibiotics in hand lacerations. Br J Surg 1977; 64:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/18\">",
"      Beesley JR, Bowden G, Hardy RH, Reynolds TD. Prophylactic antibiotics in minor hand injuries. Injury 1975; 6:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/19\">",
"      Gellman H. Fingertip-nail bed injuries in children: current concepts and controversies of treatment. J Craniofac Surg 2009; 20:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/20\">",
"      Russell RC, Casas LA. Management of fingertip injuries. Clin Plast Surg 1989; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4472/abstract/21\">",
"      Fetter-Zarzeka A, Joseph MM. Hand and fingertip injuries in children. Pediatr Emerg Care 2002; 18:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13878 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-6DBE490E2D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4472=[""].join("\n");
var outline_f4_23_4472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17719381\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17719229\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1958511\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17719243\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2001263\">",
"      INDICATIONS, CONTRAINDICATIONS, AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1959144\">",
"      Indications for subspecialty consultation or referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17719257\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452522\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452530\">",
"      Patient counseling and informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452538\">",
"      Local anesthesia, analgesia, and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2002221\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452546\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H330664\">",
"      Fingertip skin avulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17719301\">",
"      Nail bed injury and repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1959042\">",
"      Partial fingertip avulsion or amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1959050\">",
"      Complete fingertip avulsions or amputations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2278833\">",
"      ADDITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28679206\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28679222\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2278519\">",
"      Wound care and patient instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2278841\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1958641\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17719381\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13878|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/43/25267\" title=\"figure 1\">",
"      Nail anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13878|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/23/10623\" title=\"picture 1\">",
"      Digital tourniquet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/9/15504\" title=\"picture 2\">",
"      Fingertip avulsion repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/0/40974\" title=\"picture 3\">",
"      Nail bed repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/55/2931\" title=\"picture 4\">",
"      Nail bed splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/13/26836\" title=\"picture 5\">",
"      Foil splint for fingertip avulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13878|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=related_link\">",
"      Digit dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=related_link\">",
"      Subungual hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_23_4473="Caustic esophageal injury in children";
var content_f4_23_4473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Caustic esophageal injury in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4473/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4473/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4473/contributors\">",
"     Douglas S Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4473/contributors\">",
"     Craig Jensen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4473/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/23/4473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prevention of accidental ingestion of caustic agents continues to be a major concern for pediatric emergency department clinicians and the many pediatric sub-specialties involved in the management of the acute injury and long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Caustic ingestion is seen most often in young children between one and three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6\">",
"     6",
"    </a>",
"    ], with boys accounting for 50 to 62 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF INGESTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://www.aapcc.org/data-system/\">",
"     National Poison Data System",
"    </a>",
"    (NPDS) compiles data annually from a population of approximately 300 million people served by the American Association of Poison Control Centers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/7\">",
"     7",
"    </a>",
"    ]. In 2008, more than 1.6 million toxic exposures in children occurred, accounting for 65 percent of all toxic exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/7\">",
"     7",
"    </a>",
"    ]. The most common agents were cosmetic and personal care products, analgesics, and cleaning substances. Alkaline agents were more commonly ingested than were acids, and household bleaches a common cause of accidental poisonings in young children. Other products most often involved included automatic dishwasher agents, laundry detergents, swimming pool products, and toilet bowl and oven cleaners.",
"   </p>",
"   <p>",
"    Most ingestions by children are accidental and the amounts ingested tend to be small. The opposite is the case in adults, in whom ingestion often is deliberate and related to attempted suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In such cases the amount ingested may be large and the injury to the esophagus and stomach often severe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/10\">",
"     10",
"    </a>",
"    ]. Cases of alkali ingestion as a result of child abuse have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELATIONSHIP OF INGESTION TO TYPE OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the lips, oropharynx, and upper airway may occur with many caustic agents, but esophageal burns account for most of the serious injuries and chronic complications. Esophageal burns have been reported in 18 to 46 percent of caustic ingestions occurring in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6,13-18\">",
"     6,13-18",
"    </a>",
"    ], most often from common household cleaning products, such as oven and drain cleaners, strong lyes that contain sodium and potassium hydroxides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/1,6,19\">",
"     1,6,19",
"    </a>",
"    ], and laundry detergents and cleaning agents with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    , sodium carbonate, and ammonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/2,3,20\">",
"     2,3,20",
"    </a>",
"    ]. Concentrated laundry detergent packaged into single-use &ldquo;capsules&rdquo; &ldquo;gel packs&rdquo; or &ldquo;pods&rdquo; has caused multiple cases of esophageal injury and airway compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/21\">",
"     21",
"    </a>",
"    ]. These products typically are small and colorful, looking somewhat like candy. In 2012, the American Association of Poison Control Centers issued a",
"    <a class=\"external\" href=\"file://www.aapcc.org/alerts/laundry-detergent-packets/\">",
"     safety warning",
"    </a>",
"    about this new type of product [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/22\">",
"     22",
"    </a>",
"    ]. Button batteries lodged in the esophagus can rapidly cause esophageal injury, in part due to leakage of alkaline material. This issue is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link\">",
"     \"Button and cylindrical battery ingestion\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Cosmetic products such as hair relaxers are ingested commonly, but they appear to be rare causes of esophageal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one review of 29 patients with hair relaxer ingestions who underwent upper endoscopy, 6 patients (20 percent) had esophageal mucosal injury and 5 patients (17 percent) had gastric mucosal injury, but these injuries were limited to Grade 1 (superficial) injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common acid household products include toilet bowel cleaners, battery fluids, and muriatic (hydrochloric) acid used in swimming pools [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. Children living on farms may be at particularly high risk for incurring serious burns, because industrial-strength agents are in common use in that setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal burns are rare with household bleaches (sodium hypochlorite) because they have a relatively neutral pH [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. When burns do occur with these agents, they tend to be mild and do not require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ]. Industrial strength bleaches or household bleaches from other countries may be much more corrosive because of a higher concentration of sodium hypochlorite [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Solid caustic materials, which tend to adhere to the mucosa, can produce deep burns of the oral cavity and esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/30\">",
"     30",
"    </a>",
"    ], but they are less likely to reach the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/32\">",
"     32",
"    </a>",
"    ]. The immediate and severe pain produced by these products may limit the amount ingested and thus lessen the extent of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/33\">",
"     33",
"    </a>",
"    ]. Powdered or granular detergents tend to injure the upper airway, resulting in stridor and epiglottitis, whereas esophageal injury is less common [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of injury: alkali versus acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkalis and acids produce tissue injury by different mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkali &mdash; The course of injury and repair in experimentally-induced alkali burns of the esophagus has been well demonstrated in animal models [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/35\">",
"       35",
"      </a>",
"      ]. Alkalis, with a pH greater than seven, cause liquefaction necrosis. This type of injury leads to early disintegration of the mucosa, allowing deep penetration and even perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Agents with a pH of 11 or higher cause the most severe burns, even with ingestion of small amounts [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/33\">",
"       33",
"      </a>",
"      ]. Household detergents and phosphates, with pHs ranging from 9 to 11, rarely cause serious injuries unless taken in large amounts [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6,36\">",
"       6,36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Penetration into the esophageal wall by alkaline agents varies with the concentration and the length of time the agent remains in contact with the mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/37\">",
"       37",
"      </a>",
"      ]. Experimentally, a 10 percent solution of sodium hydroxide may require as long as one minute of contact to produce a deep burn, whereas as little as 1 mL of 30 percent sodium hydroxide can cause transmural esophageal necrosis within one second of contact [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/19\">",
"       19",
"      </a>",
"      ]. In animal experiments, even weakly concentrated alkaline agents (eg, 1.8 percent sodium hydroxide) can produce superficial necrosis if left in contact with the mucosa for one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acids &mdash; Acids or corrosives, with a pH less than seven, cause coagulation necrosis. However, esophageal injury from acids may be attenuated compared with alkalis because the coagulum that forms on the mucosal surface may limit deeper penetration of the caustic substance [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/29\">",
"       29",
"      </a>",
"      ]. The alkaline pH and squamous epithelium of the esophagus also help limit the severity of esophageal injury from acids. Although perforation of the esophagus is less common with ingestion of acids, the esophagus is not spared from injury because 6 to 20 percent of these ingestions result in esophageal burns [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4,14,30,38\">",
"       4,14,30,38",
"      </a>",
"      ]. Upper airway injuries also are common with ingestion of acids, perhaps related to their bad taste, which tends to stimulate gagging, choking, and attempts to spit out the ingested material [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Delayed injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial necrosis (whether caused by alkali or acid), additional destruction takes place over the first week caused by inflammation and vascular thrombosis (",
"    <a class=\"graphic graphic_table graphicRef68864 \" href=\"UTD.htm?1/63/2043\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. By 10 days there is formation of granulation tissue and weakening of the esophageal wall. During this early period, the esophagus is increasingly vulnerable to perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6,41\">",
"     6,41",
"    </a>",
"    ]. By three weeks, fibrogenesis and stricture formation are well under way, and perforation is less likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gastric injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and severity of gastric lesions in caustic ingestion have not been described extensively in part because this type of injury is less common than esophageal injury and because of the use in older reports of rigid endoscopes that frequently were not advanced beyond the first visible esophageal burn [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/31\">",
"     31",
"    </a>",
"    ]. In a review in which flexible endoscopes were used to evaluate 156 children with caustic ingestion, 17 (11 percent) had esophageal and gastric burns and 14 (9 percent) had gastric burns only [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric injury has been described in more than 80 percent of patients who ingested relatively large amounts of alkali (200 to 300 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/10\">",
"     10",
"    </a>",
"    ]. Large ingestions have resulted in gastric perforation, hemorrhage, and death from erosion into a bronchial vein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric injury often is most severe with acids, such as sulfuric acid, which (because of pooling in the antrum and antral spasm) may cause severe burns in the prepyloric area, potentially leading to pyloric obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/30\">",
"     30",
"    </a>",
"    ]. In a review of 98 children with ingestion of acid substances, 8 (8.2 percent) developed gastric outlet obstruction at a mean of 27 days after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/42\">",
"     42",
"    </a>",
"    ]. All required gastrojejunostomy. In a smaller series of 20 patients with gastric outlet obstruction, two also had esophageal strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/43\">",
"     43",
"    </a>",
"    ]. Surgery included gastroduodenostomy in eight, Billroth one in seven, and pyloroplasty in five. Duodenal erosions have been reported in occasional cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of caustic ingestions vary widely. Early signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms may not correlate with the severity and extent of tissue injury. The most common symptom is dysphagia, which can occur even without severe esophageal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4\">",
"     4",
"    </a>",
"    ]. Esophageal studies during the acute phase of injury have shown loss of motility with delayed transit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/44\">",
"     44",
"    </a>",
"    ], similar to what is seen in peptic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Prolonged esophageal transit time as measured by radionuclide testing may persist for several weeks following severe esophageal burns. Persistent dysphagia also may be caused by fibrosis of deeper muscle layers, with or without stricture formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/44\">",
"     44",
"    </a>",
"    ]. Fibrosis alone produces a decrease in the amplitude of esophageal contractions and elevated basal pressure.",
"   </p>",
"   <p>",
"    Patients may also present with drooling, retrosternal or abdominal pain, hematemesis, and features suggesting upper airway injury such as stridor, hoarseness, nasal flaring, and retractions. Epiglottitis can be severe, especially in children younger than two years of age, requiring prompt intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/33,47\">",
"     33,47",
"    </a>",
"    ]. Although symptoms of upper airway injury usually begin rapidly after contact with caustic agents, there may be a one- to two-hour delay with ingestion of powdered agents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/33\">",
"     33",
"    </a>",
"    ]. Deep esophageal burns can be complicated by esophageal perforation with mediastinitis and the development of a tracheoesophageal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence or absence of any of the clinical features described above does not predict ingestion or the presence or severity of esophageal or gastric burns. In a single series of 378 caustic ingestions in children, 12 percent had no symptoms but had severe esophageal burns, whereas 82 percent who were symptomatic at presentation had minimal or no esophageal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4\">",
"     4",
"    </a>",
"    ]. The presence or absence of oral lesions also is a poor predictor of esophageal injury. In a review of multiple case series totaling 489 children, 45 percent without oral burns had esophageal burns, and 54 percent with oral burns had accompanying esophageal burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation usually involves an upper endoscopy, which can evaluate the extent of injury. All patients with significant burns and the potential for stricture formation should be evaluated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    contrast studies two to three weeks post ingestion (",
"    <a class=\"graphic graphic_algorithm graphicRef70113 \" href=\"UTD.htm?3/28/3520\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptomatic ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documenting the presence or absence of esophageal or gastric injury after symptomatic caustic ingestion is essential because it is the only way to determine the extent of injury and thereby predict prognosis. The most reliable method is by upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/16,18\">",
"     16,18",
"    </a>",
"    ], which is typically performed within the first 24 to 48 hours. Earlier endoscopy may not show the full extent of the injury and endoscopy after four days increases the risk of perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6,16,18,29,48,49\">",
"     6,16,18,29,48,49",
"    </a>",
"    ]. The objectives of early endoscopy are to establish the presence or absence of esophageal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastric lesions and to determine the severity of involvement. Once the extent of injury is known, appropriate therapy can be initiated.",
"   </p>",
"   <p>",
"    Flexible video endoscopes have made upper endoscopy safer, and in all but the most severe cases flexible scopes can be passed through the esophagus and into the stomach, even if esophageal burns are noted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6,10,16,18\">",
"     6,10,16,18",
"    </a>",
"    ]. Flexible endoscopes also allow the use of conscious (intravenous) sedation in an outpatient setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/20\">",
"     20",
"    </a>",
"    ]. On the other hand, endoscopy should be performed using general anesthesia and protection of the airway in patients with severe burns and with upper airway signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/20\">",
"     20",
"    </a>",
"    ]. Endoscopy is contraindicated in patients who are hemodynamically unstable, have evidence of perforation or severe respiratory distress, or exhibit severe oropharyngeal or glottic edema and necrosis. Rigid endoscopes are still used commonly, but the risk of perforation remains a major consideration, and these endoscopes generally are not advanced beyond the first significant esophageal burn [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiologic examination is valuable and essential for follow-up to detect the presence of strictures. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies are not reliable in detecting acute injury or in predicting stricture formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/8,50\">",
"     8,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Asymptomatic ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors suggest endoscopy in all children with any hint of caustic ingestion because the history regarding ingestion may be vague and symptoms in young children may be unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. However, in patients with a questionable history of ingestion, no evidence of oral lesions, and no dysphagia, vomiting, or other symptoms, it generally is safe to observe fluid intake and overall status over several hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4,5,51\">",
"     4,5,51",
"    </a>",
"    ]. Endoscopy may be unnecessary if the patient remains asymptomatic with normal swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/13,14,31,49\">",
"     13,14,31,49",
"    </a>",
"    ]. Patients with a definite history or strong suggestion of ingestion even if asymptomatic, and patients with symptoms or oral burns, should be evaluated with upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6,45,51\">",
"     6,45,51",
"    </a>",
"    ]. One exception is in patients who have ingested household bleaches, in whom significant injury is rare and endoscopy is usually unnecessary. &nbsp;",
"   </p>",
"   <p>",
"    A grading system for esophageal burns has been useful in planning appropriate medical therapy, documenting the need for a nasogastric tube, and predicting later stricture formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/32\">",
"     32",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77228 \" href=\"UTD.htm?7/18/7467\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-degree burns are those with injury limited to edema and erythema.",
"     </li>",
"     <li>",
"      Second-degree burns are characterized by linear ulceration and necrotic tissue with whitish plaques. Grade 2A are localized or partial and Grade 2B are circumferential.",
"     </li>",
"     <li>",
"      Third-degree burns include circumferential injury with sloughing of the mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/16,32\">",
"       16,32",
"      </a>",
"      ]. Some authors use third-degree burns to define patients with perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4\">",
"       4",
"      </a>",
"      ]. Linear burns rarely lead to stenosis, whereas circumferential burns frequently heal with stricture formation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of caustic ingestion primarily is observation, with an emphasis on preventing vomiting, choking, and aspiration. The induction of vomiting is contraindicated because vomiting may lead to additional esophageal injury if gastric contents come in contact with the esophageal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the use of neutralizing agents has been proposed, this type of therapy generally is not recommended because there is concern about additional damage from heat injury during the neutralization process [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/53\">",
"     53",
"    </a>",
"    ]. Similarly, the use of diluting agents, such as milk or water, has been recommended by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/31\">",
"     31",
"    </a>",
"    ]. However, ingestion of a large volume of a diluting agent can induce vomiting, potentially leading to further complications. In the presence of acute airway swelling and obstruction, diluting agents clearly are contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, the amount of milk or other fluids that would be necessary to significantly dilute a caustic agent is too large to make such therapy practical. Thus,",
"    <strong>",
"     no",
"    </strong>",
"    attempts at either dilution or neutralization can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nasogastric tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients in whom extensive circumferential burns (Grade 2B or 3) are seen during upper endoscopy, a nasogastric tube (NGT) should be placed under direct visualization during the endoscopic procedure. A NGT should",
"    <strong>",
"     not",
"    </strong>",
"    be inserted blindly because perforation or additional injury can occur while passing the tube. The NGT can provide a route for nutritional support during the healing phase, and help maintain a lumen during stricture formation. It also can serve as a guide for esophageal dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/54\">",
"     54",
"    </a>",
"    ]. Older studies using silicone NGTs (ranging in size from 5 to 10 mm) suggested that they may prevent the development of serious strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Such therapy was tried primarily in patients with circular, deeply ulcerated caustic injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preponderance of evidence suggests that the use of corticosteroids in adults and children with caustic esophageal injuries does not help protect against the development of esophageal strictures, and may be harmful.",
"   </p>",
"   <p>",
"    The rationale for the use of steroids was based upon early animal studies, which demonstrated that corticosteroids prevented esophageal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/35,58,59\">",
"     35,58,59",
"    </a>",
"    ], and a few small case series, which suggested a benefit in patients with first-or second-degree esophageal burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/8,30,60\">",
"     8,30,60",
"    </a>",
"    ]. In contrast, larger studies have shown no benefit (and possible harm) with the use of corticosteroids, as strictures developed in 20 to 38 percent of documented esophageal burns, regardless of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/16\">",
"     16",
"    </a>",
"    ]. This is particularly true for patients with third-degree burns, in whom stricture formation appears to be inevitable regardless of therapy. In addition, perforation is also common in such patients, the presentation of which can be masked by corticosteroids.",
"   </p>",
"   <p>",
"    The largest controlled trial to address the issue included 60 children who were assigned randomly to receive a placebo or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) followed by three weeks of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/16\">",
"     16",
"    </a>",
"    ]. Stricture formation appeared to be related only to the severity of the caustic injury, not the use of prednisolone. A 2005 review of the value of corticosteroids examined 10 retrospective reports on caustic ingestion between 1991 and 2004, including a total of 572 patients, and concluded that there was no benefit in using corticosteroids for grade 2 or 3 burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/61\">",
"     61",
"    </a>",
"    ]. Similarly, a pooled analysis of 13 retrospective series of patients with grade 2 burns found no benefit in using corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/62\">",
"     62",
"    </a>",
"    ]. The majority of patients in these case series are in the pediatric age range. &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Corticosteroids also should not be used for acid ingestion because esophageal strictures are less likely and there is a greater risk of masking the clinical features of gastric necrosis and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Early dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early dilatation to prevent stricture formation has been tried, but the increased incidence of perforation has limited its use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastrostomy tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe burns with highly caustic materials, such as industrial-strength lye, extensive esophageal injury is common. A gastrostomy can be helpful and should be considered at initial evaluation for placement of a string that can be used later for retrograde dilatation. Unlike an NG tube, which can be pulled out inadvertently and may be impossible to replace, a string is unlikely to be pulled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LATE COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20530365\">",
"    <span class=\"h2\">",
"     Stricture formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stricture formation is the primary complication of caustic injury, occurring in 2 to 38 percent of all ingestions and in 3 to 57 percent of ingestions with documented esophageal burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/4-6,16\">",
"     4-6,16",
"    </a>",
"    ]. Most third-degree (circumferential) burns lead to esophageal strictures regardless of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/16\">",
"     16",
"    </a>",
"    ]. Second-degree burns are less likely to result in strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/50\">",
"     50",
"    </a>",
"    ], although one report of 50 cases of caustic ingestion found that 20 percent had second-degree burns and half of these went on to esophageal stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/63\">",
"     63",
"    </a>",
"    ]. Although there are rare reports of patients developing strictures following a normal endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/6\">",
"     6",
"    </a>",
"    ], it is likely that a burn was present but was missed using a rigid endoscope.",
"   </p>",
"   <p>",
"    Approximately 80 percent of patients who develop a stricture will have obstructive symptoms within two months. In patients with the most severe burns, there may be complete obstruction within three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/64\">",
"     64",
"    </a>",
"    ]. At six weeks, the esophagram shows a long constriction. Severe stricture commonly is still present after two years, despite repeated dilation.",
"   </p>",
"   <p>",
"    Once a stricture is confirmed radiologically, esophageal dilatation usually is required to maintain or reestablish normal swallowing. A variety of dilators can be used, including mercury-filled bougies, Maloney antegrade dilators or Tucker dilators used in retrograde dilatation, and dilators passed over a string or guide wire. Because caustic strictures appear to perforate easily, retrograde dilatation has been considered the safest method, although this method requires a gastrostomy and a string for guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/54\">",
"     54",
"    </a>",
"    ]. Balloon dilators under endoscopic control are also commonly used in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Perforation should be less likely with these instruments because only radially directed force is exerted, and the longitudinal shearing force with ante grade and retrograde dilators is avoided. However, balloon dilatation is not totally free from complications because even this technique has resulted in esophageal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although esophageal dilatation may be beneficial initially, repeated dilatations usually are needed. Only 33 to 48 percent of patients with caustic strictures have long-term success with repeated dilatations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. The remaining patients, who often have long strictures, have increasing difficulty in swallowing because of progressive obstruction. Many of these patients have extensive strictures that ultimately require esophagectomy with colon interposition within two years following the ingestion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74287 \" href=\"UTD.htm?29/45/30431\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. Although colon interposition can be successful, many patients have persistent difficulty swallowing. In addition, anastomotic strictures may need periodic dilatation, and reflux of gastric contents can produce gastrocolic ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    C, an inhibitor of fibroblast proliferation, has been used in children who have required repeated dilatations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Although there are no controlled trials, the application of mitomycin C to the surface of the stenotic esophagus right after dilatation has been reported to decrease the need for further dilatation. A retrospective case series from eight institutions in Europe, Australia and the United States described 16 patients with esophageal strictures, 10 of which were caused by caustic ingestion. Each was treated with topical mitomycin C following esophageal dilatation. The treatment was successful in eliminating or reducing the need for repeated dilatations in 82 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal stenting has been described in limited series for use in chronic stricture management secondary to caustic ingestions. They have also been used in children after surgery for congenital strictures and esophageal injury from batteries, with mixed success [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20530372\">",
"    <span class=\"h2\">",
"     Carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following colonic interposition, caustic injury appears to lead to an increased risk of carcinoma in the bypassed esophagus, with a reported incidence of 2 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/32\">",
"     32",
"    </a>",
"    ]. The time interval between ingestion and the detection of tumor has ranged from 16 to 42 years, and there is some speculation that the true incidence of carcinoma could reach 30 percent or more if patients were followed for 30 years. Although removing the esophagus is a difficult procedure, some authors now recommend resection at the time of bypass with colon interposition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/32\">",
"     32",
"    </a>",
"    ]. Any patient with a history of caustic ingestion and the late onset or worsening of dysphagia should be evaluated promptly, and carcinoma should be suspected until proved otherwise.",
"   </p>",
"   <p>",
"    Late development of carcinoma is also possible in patients who have a stricture but have not needed a colonic interposition. Since carcinomas tend to occur in strictured areas, they are often resectable, but survival rate is poor (40 percent at 1 year and 13 percent at 5 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/75\">",
"     75",
"    </a>",
"    ]. There is some controversy regarding the value of periodic screening for the development of dysplasia or carcinoma, but periodic endoscopy with cytological study of washings and biopsy should be considered in patients who are 20 years or more from initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20530379\">",
"    <span class=\"h2\">",
"     Pyloric stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyloric stenosis can occur with both acids and alkalis and often is associated with esophageal injury and strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/38\">",
"     38",
"    </a>",
"    ]. With severe injury to the stomach, gastric outlet obstruction may occur as early as three weeks or as late as 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/38,76\">",
"     38,76",
"    </a>",
"    ]. Surgical bypass may be necessary, but endoscopic balloon dilatation also has been used successfully in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4473/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20529740\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal burns account for most of the serious injuries and chronic complications of caustic ingestion. Injury to the lips, oropharynx, and upper airway also may occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of ingestion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most common causes of caustic esophageal burns are alkaline household cleaning products, such as oven and drain cleaners, strong lyes that contain sodium and potassium hydroxides, and laundry detergents and cleaning agents with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      , sodium carbonate, and ammonia. Esophageal burns are rare with household bleaches (sodium hypochlorite) because these have a relatively neutral pH.",
"     </li>",
"     <li>",
"      Some caustic ingestions are caused by acid household products including toilet bowel cleaners, battery fluids, and muriatic (hydrochloric) acid used in swimming pools. Esophageal injury from acids may be attenuated compared with alkalis, and perforation of the esophagus is less common. Nonetheless, 6 to 20 percent of acid ingestions result in esophageal burns. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanisms of injury: alkali versus acids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following the initial necrosis, additional destruction takes place over the first week (",
"      <a class=\"graphic graphic_table graphicRef68864 \" href=\"UTD.htm?1/63/2043\">",
"       table 1",
"      </a>",
"      ). The risk for esophageal perforation peaks at this stage. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Delayed injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptom is dysphagia, which can occur even without severe esophageal injury. Patients may also present with drooling, retrosternal or abdominal pain, hematemesis, and features suggesting upper airway injury. The presence or absence of any of the clinical features described above does not predict ingestion or the presence or severity of esophageal or gastric burns. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Upper endoscopy is recommended for most patients with a definite history of caustic ingestion, even if asymptomatic; endoscopy should definitely be performed in patients with symptoms or oral lesions (",
"      <a class=\"graphic graphic_algorithm graphicRef70113 \" href=\"UTD.htm?3/28/3520\">",
"       algorithm 1",
"      </a>",
"      ). Endoscopy is contraindicated in patients who are hemodynamically unstable, have evidence of perforation or severe respiratory distress, or exhibit severe oropharyngeal or glottic edema and necrosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptomatic ingestion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with significant burns and the potential for stricture formation should be evaluated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      contrast studies two to three weeks post ingestion. Contrast studies are not reliable in detecting acute injury or in predicting stricture formation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy is generally unnecessary in patients with a questionable history of ingestion, no evidence of oral lesions, no dysphagia, vomiting, or other symptoms, and who remain asymptomatic and continue to swallow normally during several hours of observation. Patients who have ingested household bleaches rarely have significant tissue injury and, therefore, rarely require endoscopy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Asymptomatic ingestion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial treatment of caustic ingestion primarily is observation, with an emphasis on preventing vomiting, choking, and aspiration. The induction of vomiting is contraindicated because vomiting may lead to additional esophageal injury if gastric contents come in contact with the esophageal mucosa. We do",
"      <strong>",
"       not",
"      </strong>",
"      recommend attempts to dilute or neutralize the ingested agent because these are not effective in preventing esophageal injury and may lead to vomiting. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest AGAINST using corticosteroids in children with caustic esophageal injuries (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A preponderance of evidence suggests that these agents do not help protect against the development of esophageal strictures and may be harmful. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stricture formation is the primary complication of caustic injury. Most patients who develop strictures present with obstructive symptoms within two months. The presence of a stricture is confirmed radiologically, and esophageal dilatation usually is used to maintain or reestablish normal swallowing. (See",
"      <a class=\"local\" href=\"#H20530365\">",
"       'Stricture formation'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/1\">",
"      Nuutinen M, Uhari M, Karvali T, Kouvalainen K. Consequences of caustic ingestions in children. Acta Paediatr 1994; 83:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/2\">",
"      Byrne WJ. Foreign bodies, bezoars, and caustic ingestion. Gastrointest Endosc Clin N Am 1994; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/3\">",
"      Wasserman RL, Ginsburg CM. Caustic substance injuries. J Pediatr 1985; 107:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/4\">",
"      Gaudreault P, Parent M, McGuigan MA, et al. Predictability of esophageal injury from signs and symptoms: a study of caustic ingestion in 378 children. Pediatrics 1983; 71:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/5\">",
"      Moazam F, Talbert JL, Miller D, Mollitt DL. Caustic ingestion and its sequelae in children. South Med J 1987; 80:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/6\">",
"      Adam JS, Birck HG. Pediatric caustic ingestion. Ann Otol Rhinol Laryngol 1982; 91:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/7\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/8\">",
"      Borja AR, Ransdell HT Jr, Thomas TV, Johnson W. Lye injuries of the esophagus. Analysis of ninety cases of lye ingestion. J Thorac Cardiovasc Surg 1969; 57:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/9\">",
"      Ar&eacute;valo-Silva C, Eliashar R, Wohlgelernter J, et al. Ingestion of caustic substances: a 15-year experience. Laryngoscope 2006; 116:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/10\">",
"      Cello JP, Fogel RP, Boland CR. Liquid caustic ingestion. Spectrum of injury. Arch Intern Med 1980; 140:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/11\">",
"      Friedman EM. Caustic ingestions and foreign body aspirations: an overlooked form of child abuse. Ann Otol Rhinol Laryngol 1987; 96:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/12\">",
"      Dine MS, McGovern ME. Intentional poisoning of children--an overlooked category of child abuse: report of seven cases and review of the literature. Pediatrics 1982; 70:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/13\">",
"      Gupta SK, Croffie JM, Fitzgerald JF. Is esophagogastroduodenoscopy necessary in all caustic ingestions? J Pediatr Gastroenterol Nutr 2001; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/14\">",
"      Lamireau T, Rebouissoux L, Denis D, et al. Accidental caustic ingestion in children: is endoscopy always mandatory? J Pediatr Gastroenterol Nutr 2001; 33:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/15\">",
"      de Jong AL, Macdonald R, Ein S, et al. Corrosive esophagitis in children: a 30-year review. Int J Pediatr Otorhinolaryngol 2001; 57:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/16\">",
"      Anderson KD, Rouse TM, Randolph JG. A controlled trial of corticosteroids in children with corrosive injury of the esophagus. N Engl J Med 1990; 323:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/17\">",
"      Haller JA Jr, Andrews HG, White JJ, et al. Pathophysiology and management of acute corrosive burns of the esophagus: results of treatment in 285 children. J Pediatr Surg 1971; 6:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/18\">",
"      Previtera C, Giusti F, Guglielmi M. Predictive value of visible lesions (cheeks, lips, oropharynx) in suspected caustic ingestion: may endoscopy reasonably be omitted in completely negative pediatric patients? Pediatr Emerg Care 1990; 6:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/19\">",
"      Leape LL, Ashcraft KW, Scarpelli DG, Holder TM. Hazard to health--liquid lye. N Engl J Med 1971; 284:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/20\">",
"      Moore WR. Caustic ingestions. Pathophysiology, diagnosis, and treatment. Clin Pediatr (Phila) 1986; 25:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/21\">",
"      Fraser L, Wynne D, Clement WA, et al. Liquid detergent capsule ingestion in children: an increasing trend. Arch Dis Child 2012; 97:1007.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Poison Control Centers (AAPC) safety warning, issued May 2012. Available at: file://www.aapcc.org/alerts/laundry-detergent-packets/ (Accessed on November 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/23\">",
"      Stenson K, Gruber B. Ingestion of caustic cosmetic products. Otolaryngol Head Neck Surg 1993; 109:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/24\">",
"      Ahsan S, Haupert M. Absence of esophageal injury in pediatric patients after hair relaxer ingestion. Arch Otolaryngol Head Neck Surg 1999; 125:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/25\">",
"      Aronow SP, Aronow HD, Blanchard T, et al. Hair relaxers: a benign caustic ingestion? J Pediatr Gastroenterol Nutr 2003; 36:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/26\">",
"      Zargar SA, Kochhar R, Nagi B, et al. Ingestion of corrosive acids. Spectrum of injury to upper gastrointestinal tract and natural history. Gastroenterology 1989; 97:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/27\">",
"      Edmonson MB. Caustic alkali ingestions by farm children. Pediatrics 1987; 79:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/28\">",
"      Harley EH, Collins MD. Liquid household bleach ingestion in children: a retrospective review. Laryngoscope 1997; 107:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/29\">",
"      Friedman EM. Caustic ingestions and foreign bodies in the aerodigestive tract of children. Pediatr Clin North Am 1989; 36:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/30\">",
"      Hawkins DB, Demeter MJ, Barnett TE. Caustic ingestion: controversies in management. A review of 214 cases. Laryngoscope 1980; 90:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/31\">",
"      Wason S. The emergency management of caustic ingestions. J Emerg Med 1985; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/32\">",
"      Kirsh MM, Ritter F. Caustic ingestion and subsequent damage to the oropharyngeal and digestive passages. Ann Thorac Surg 1976; 21:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/33\">",
"      Einhorn A, Horton L, Altieri M, et al. Serious respiratory consequences of detergent ingestions in children. Pediatrics 1989; 84:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/34\">",
"      Wheeler DS, Bonny AE, Ruddy RM, Jacobs BR. Late-onset respiratory distress after inhalation of laundry detergent. Pediatr Pulmonol 2003; 35:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/35\">",
"      HALLER JA, BACHMAN K. THE COMPARATIVE EFFECT OF CURRENT THERAPY ON EXPERIMENTAL CAUSTIC BURNS OF THE ESOPHAGUS. Pediatrics 1964; 34:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/36\">",
"      M&uuml;hlendahl KE, Oberdisse U, Krienke EG. Local injuries by accidental ingestion of corrosive substances by children. Arch Toxicol 1978; 39:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/37\">",
"      Mattos GM, Lopes DD, Mamede RC, et al. Effects of time of contact and concentration of caustic agent on generation of injuries. Laryngoscope 2006; 116:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/38\">",
"      Maull KI, Scher LA, Greenfield LJ. Surgical implications of acid ingestion. Surg Gynecol Obstet 1979; 148:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/39\">",
"      Dafoe CS, Ross CA. Acute corrosive oesophagitis. Thorax 1969; 24:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/40\">",
"      JOHNSON EE. A STUDY OF CORROSIVE ESOPHAGITIS. Laryngoscope 1963; 73:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/41\">",
"      Tewfik TL, Schloss MD. Ingestion of lye and other corrosive agents--a study of 86 infant and child cases. J Otolaryngol 1980; 9:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/42\">",
"      Ozcan C, Erg&uuml;n O, Sen T, Mutaf O. Gastric outlet obstruction secondary to acid ingestion in children. J Pediatr Surg 2004; 39:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/43\">",
"      Ozokutan BH, Ceylan H, Erta��kin I, Yapici S. Pediatric gastric outlet obstruction following corrosive ingestion. Pediatr Surg Int 2010; 26:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/44\">",
"      Cadranel S, Di Lorenzo C, Rodesch P, et al. Caustic ingestion and esophageal function. J Pediatr Gastroenterol Nutr 1990; 10:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/45\">",
"      Cucchiara S, Staiano A, Di Lorenzo C, et al. Esophageal motor abnormalities in children with gastroesophageal reflux and peptic esophagitis. J Pediatr 1986; 108:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/46\">",
"      Hillemeier AC, Grill BB, McCallum R, Gryboski J. Esophageal and gastric motor abnormalities in gastroesophageal reflux during infancy. Gastroenterology 1983; 84:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/47\">",
"      Moulin D, Bertrand JM, Buts JP, et al. Upper airway lesions in children after accidental ingestion of caustic substances. J Pediatr 1985; 106:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/48\">",
"      Zargar SA, Kochhar R, Mehta S, Mehta SK. The role of fiberoptic endoscopy in the management of corrosive ingestion and modified endoscopic classification of burns. Gastrointest Endosc 1991; 37:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/49\">",
"      Christesen HB. Prediction of complications following unintentional caustic ingestion in children. Is endoscopy always necessary? Acta Paediatr 1995; 84:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/50\">",
"      Ferguson MK, Migliore M, Staszak VM, Little AG. Early evaluation and therapy for caustic esophageal injury. Am J Surg 1989; 157:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/51\">",
"      Wilsey MJ Jr, Scheimann AO, Gilger MA. The role of upper gastrointestinal endoscopy in the diagnosis and treatment of caustic ingestion, esophageal strictures, and achalasia in children. Gastrointest Endosc Clin N Am 2001; 11:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/52\">",
"      Kleager LE, Yarington CT Jr. Emergency management of esophageal burns: a review for the primary health care physician. Nebr Med J 1974; 59:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/53\">",
"      Maull KI, Osmand AP, Maull CD. Liquid caustic ingestions: an in vitro study of the effects of buffer, neutralization, and dilution. Ann Emerg Med 1985; 14:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/54\">",
"      Hawkins DB. Dilation of esophageal strictures: comparative morbidity of antegrade and retrograde methods. Ann Otol Rhinol Laryngol 1988; 97:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/55\">",
"      Reyes HM, Hill JL. Modification of the experimental stent technique for esophageal burns. J Surg Res 1976; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/56\">",
"      Wijburg FA, Heymans HS, Urbanus NA. Caustic esophageal lesions in childhood: prevention of stricture formation. J Pediatr Surg 1989; 24:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/57\">",
"      Grundy A. The Strecker Esophageal stent in the management of oesophageal strictures: technique of insertion and early clinical experience. Clin Radiol 1994; 49:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/58\">",
"      ROSENBERG N, KUNDERMAN PJ, VROMAN L, MOOLTEN SE. Prevention of experimental esophageal stricture by cortisone. II. Control of suppurative complications by penicillin. AMA Arch Surg 1953; 66:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/59\">",
"      WEISSKOPF A. Effects of cortisone on experimental lye burn of the esophagus. Ann Otol Rhinol Laryngol 1952; 61:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/60\">",
"      CLEVELAND WW, THORNTON N, CHESNEY JG, LAWSON RB. The effect of prednisone in the prevention of esophageal stricture following the ingestion of lye. South Med J 1958; 51:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/61\">",
"      Pelclov&aacute; D, Navr&aacute;til T. Do corticosteroids prevent oesophageal stricture after corrosive ingestion? Toxicol Rev 2005; 24:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/62\">",
"      Fulton JA, Hoffman RS. Steroids in second degree caustic burns of the esophagus: a systematic pooled analysis of fifty years of human data: 1956-2006. Clin Toxicol (Phila) 2007; 45:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/63\">",
"      Riffat F, Cheng A. Pediatric caustic ingestion: 50 consecutive cases and a review of the literature. Dis Esophagus 2009; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/64\">",
"      Webb WR, Koutras P, Ecker RR, Sugg WL. An evaluation of steroids and antibiotics in caustic burns of the esophagus. Ann Thorac Surg 1970; 9:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/65\">",
"      Song HY, Han YM, Kim HN, et al. Corrosive esophageal stricture: safety and effectiveness of balloon dilation. Radiology 1992; 184:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/66\">",
"      Sato Y, Frey EE, Smith WL, et al. Balloon dilatation of esophageal stenosis in children. AJR Am J Roentgenol 1988; 150:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/67\">",
"      Ball WS, Strife JL, Rosenkrantz J, et al. Esophageal strictures in children. Treatment by balloon dilatation. Radiology 1984; 150:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/68\">",
"      West KW, Vane DW, Grosfeld JL. Esophageal replacement in children: experience with thirty-one cases. Surgery 1986; 100:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/69\">",
"      Han MT. Ileocolic replacement of esophagus in children with esophageal stricture. J Pediatr Surg 1991; 26:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/70\">",
"      Uhlen S, Fayoux P, Vachin F, et al. Mitomycin C: an alternative conservative treatment for refractory esophageal stricture in children? Endoscopy 2006; 38:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/71\">",
"      Olutoye OO, Shulman RJ, Cotton RT. Mitomycin C in the management of pediatric caustic esophageal strictures: a case report. J Pediatr Surg 2006; 41:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/72\">",
"      Rosseneu S, Afzal N, Yerushalmi B, et al. Topical application of mitomycin-C in oesophageal strictures. J Pediatr Gastroenterol Nutr 2007; 44:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/73\">",
"      Atabek C, Surer I, Demirbag S, et al. Increasing tendency in caustic esophageal burns and long-term polytetrafluorethylene stenting in severe cases: 10 years experience. J Pediatr Surg 2007; 42:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/74\">",
"      Best C, Sudel B, Foker JE, et al. Esophageal stenting in children: indications, application, effectiveness, and complications. Gastrointest Endosc 2009; 70:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/75\">",
"      Isolauri J, Markkula H. Lye ingestion and carcinoma of the esophagus. Acta Chir Scand 1989; 155:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/76\">",
"      Tekant G, Ero��lu E, Erdo��an E, et al. Corrosive injury-induced gastric outlet obstruction: a changing spectrum of agents and treatment. J Pediatr Surg 2001; 36:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4473/abstract/77\">",
"      Treem WR, Long WR, Friedman D, Watkins JB. Successful management of an acquired gastric outlet obstruction with endoscopy guided balloon dilatation. J Pediatr Gastroenterol Nutr 1987; 6:992.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5862 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4473=[""].join("\n");
var outline_f4_23_4473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20529740\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF INGESTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELATIONSHIP OF INGESTION TO TYPE OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of injury: alkali versus acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Delayed injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gastric injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptomatic ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Asymptomatic ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nasogastric tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Early dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastrostomy tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LATE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20530365\">",
"      Stricture formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20530372\">",
"      Carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20530379\">",
"      Pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20529740\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5862\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5862|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/28/3520\" title=\"algorithm 1\">",
"      Approach caustic ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5862|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/45/30431\" title=\"diagnostic image 1\">",
"      Caustic esophageal stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5862|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/63/2043\" title=\"table 1\">",
"      Timing of tissue damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/18/7467\" title=\"table 2\">",
"      Grading of esophageal burn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=related_link\">",
"      Button and cylindrical battery ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_23_4474="Idiopathic interstitial pneumonias: Clinical manifestations and pathology";
var content_f4_23_4474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Carlyne D Cool, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/23/4474/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/23/4474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Diffuse interstitial lung disease\" (ILD) is a generic term encompassing a broad range of largely unrelated conditions that share the propensity to cause breathlessness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cough associated with bilateral abnormal opacities of various types on conventional chest radiographs or computed tomographic (CT) scans (",
"    <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The idiopathic interstitial pneumonias are a subset of diffuse interstitial lung diseases of unknown etiology characterized by expansion of the interstitial compartment (ie, that portion of the lung parenchyma sandwiched between the epithelial and endothelial basement membranes) with an infiltrate of inflammatory cells. The inflammatory infiltrate is sometimes accompanied by fibrosis, either in the form of abnormal collagen deposition or proliferation of fibroblasts capable of collagen synthesis.",
"   </p>",
"   <p>",
"    Our understanding of the idiopathic interstitial pneumonias has been plagued by our inability to clearly define the extent to which these represent distinct entities, as opposed to variations on the same fundamental theme. \"Lumpers\" have maintained that all are appropriately captured beneath the venerable umbrella of idiopathic pulmonary fibrosis (IPF, also referred to as cryptogenic fibrosing alveolitis [CFA]), and that morphologic separations are misguided attempts to segregate what are in fact highly related points on the same continuum of fibrosing lung disease. \"Splitters\" respond that failure to control for histologic subtypes has impeded our efforts to explain or predict the seemingly capricious behavior of a family of similar but separable interstitial lung diseases.",
"   </p>",
"   <p>",
"    The pathologic classification of idiopathic interstitial pneumonias is reviewed here. In additional, clinical features of each type of idiopathic interstitial pneumonia are discussed. The diagnostic approach to patients with interstitial lung disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Averill Liebow pioneered the notion that morphologic characteristics are useful in separating idiopathic interstitial pneumonias into clinically and histologically distinct groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/1\">",
"     1",
"    </a>",
"    ]. These categories of usual interstitial pneumonia (UIP) and desquamative interstitial pneumonia (DIP) have persisted as important histologic groups, while bronchiolitis obliterans with classical interstitial pneumonia (BIP) and giant cell interstitial pneumonia (GIP) have disappeared from subsequent classification schemes (",
"    <a class=\"graphic graphic_table graphicRef52032 \" href=\"UTD.htm?10/10/10412\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/2\">",
"     2",
"    </a>",
"    ]. The system outlined in the joint American Thoracic Society and European Respiratory Society statement on the histopathologic classification of idiopathic interstitial pneumonias further refines this terminology (",
"    <a class=\"graphic graphic_table graphicRef68251 \" href=\"UTD.htm?23/25/23963\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the classification of idiopathic interstitial pneumonias, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Lymphoid interstitial pneumonia (LIP) remains controversial in terms of its relationship to other idiopathic interstitial pneumonias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=see_link\">",
"     \"Lymphoid interstitial pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liebow was careful to say that these were histological patterns rather than free standing diagnostic entities, and that each could occur in a variety of clinical contexts. Regardless of the clinical context, however, he maintained that precise histological classification of interstitial pneumonias provides clues to etiology, pathogenesis, natural history, and prognosis. In other words, although individual histological patterns are not free-standing diagnostic entities, each significantly limits the differential diagnosis in terms of potential etiologies or clinical associations, and each has specific implications concerning likely treatment response and outcome.",
"   </p>",
"   <p>",
"    For patients in whom open or thoracoscopically-guided lung biopsies show the histologic patterns encompassed under the heading of idiopathic interstitial pneumonia, the biopsy is intended not only to confirm the suspicion of an interstitial pneumonia, but also to exclude various IPF mimics such as sarcoidosis, hypersensitivity pneumonitis, and pulmonary Langerhans' cell histiocytosis (",
"    <a class=\"graphic graphic_algorithm graphicRef50172 \" href=\"UTD.htm?4/32/4623\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/3\">",
"     3",
"    </a>",
"    ]. The radiologic findings and clinical course of disease may also provide substantial diagnostic clues (",
"    <a class=\"graphic graphic_table graphicRef60070 \" href=\"UTD.htm?0/15/253\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     USUAL INTERSTITIAL PNEUMONIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Usual interstitial pneumonia (UIP) is the typical pathological finding in patients with suspected idiopathic pulmonary fibrosis (IPF). An ATS consensus statement defined IPF as a specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the histologic appearance of usual interstitial pneumonia (UIP) on surgical (thoracoscopic or open) lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPF has an estimated prevalence of 14 to 43 per 100,000 and an estimated incidence of 7 to 16 per 100,000, depending on the criteria used to define IPF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Both prevalence and incidence increase with advancing age. Most cases are sporadic and present with slowly progressive dyspnea and nonproductive cough. Men are affected more commonly than women. Rare familial cases of IPF have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary function studies typically demonstrate a restrictive pattern, and chest radiographs show diffuse interstitial opacities associated with reduced lung volumes. High resolution computed tomography (HRCT) demonstrates a characteristic pattern of peripheral (subpleural) and bibasilar reticulonodular opacities associated with architectural distortion, including honeycomb changes and traction bronchiectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77526 \" href=\"UTD.htm?21/4/21569\">",
"     image 1",
"    </a>",
"    ). In the appropriate clinical setting, radiographic findings may be sufficient to establish the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef54828 \" href=\"UTD.htm?40/53/41819\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. On the other hand, HRCT may erroneously suggest an alternate diagnosis in up to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     UIP/IPF",
"    </span>",
"    usually follows a relentlessly progressive course, with most patients dying of respiratory failure within 5 to 10 years after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/14\">",
"     14",
"    </a>",
"    ]. Cigarette smoking influences survival; never smokers have a better survival than former smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/15\">",
"     15",
"    </a>",
"    ]. When survival is adjusted for disease severity, never smokers also have a better survival than current smokers.",
"   </p>",
"   <p>",
"    Periodic exacerbations are common with a two-year frequency of approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/16\">",
"     16",
"    </a>",
"    ]. Exacerbations are associated with increased dyspnea and sometimes cough. The accelerated decline in pulmonary function can be related to either variation in the tempo of the underlying lesion or superimposed complications (eg, gastroesophageal reflux, infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients succumb to respiratory failure, although other fatal complications, such as bronchogenic carcinoma, account for a significant minority of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/21\">",
"     21",
"    </a>",
"    ]. Survival may be better among patients with a higher BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/22\">",
"     22",
"    </a>",
"    ]. Treatment options are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link\">",
"     \"Treatment of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;UIP is a specific morphologic entity (",
"    <a class=\"graphic graphic_table graphicRef50587 \" href=\"UTD.htm?16/13/16603\">",
"     table 5",
"    </a>",
"    ). The histologic hallmark and chief diagnostic criterion is a heterogeneous appearance with alternating areas of normal lung, interstitial inflammation, fibroblast foci, and honeycomb change. The histological changes correlate with findings on HRCT, in that the peripheral subpleural parenchyma is most severely affected.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fibrotic zones are composed mainly of dense collagen, although scattered foci of fibroblast proliferation (\"fibroblast foci\") are a consistent finding. A morphometric analysis with three-dimensional reconstruction showed that in some cases of UIP, the fibroblast foci appear highly interconnected, forming a complex reticulum at the advancing edge of the fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interstitial inflammation is usually patchy and consists of an alveolar septal infiltrate of lymphocytes, plasma cells, and histiocytes associated with hyperplasia of type 2 pneumocytes.",
"     </li>",
"     <li>",
"      Areas of honeycomb change are composed of cystic fibrotic air spaces, which are frequently lined by bronchiolar epithelium and filled with mucin. Smooth muscle hyperplasia is commonly seen in areas of fibrosis and honeycomb change.",
"     </li>",
"     <li>",
"      Patients who are biopsied during an accelerated phase of their illness (accelerated IPF) may show a combination of UIP and a superimposed acute lung injury pattern such as diffuse alveolar damage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/18,21\">",
"       18,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insights into the pathogenesis of UIP have helped correlate histology with survival and response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In a carefully executed, prospective cohort study of 87 patients with biopsy-proven UIP, a greater degree of",
"    <span class=\"nowrap\">",
"     granulation/connective",
"    </span>",
"    tissue deposition (characteristic of fibroblast foci) was correlated with shorter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/27\">",
"     27",
"    </a>",
"    ]. This finding is consistent with the view that UIP is not a disease of active inflammation, but one of abnormal lung fibroblast proliferation and dysregulated fibrogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32378?source=see_link\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term UIP is generally reserved for those patients in whom the lesion is idiopathic. A pattern of interstitial inflammation and fibrosis indistinguishable from UIP can occur in patients with collagen vascular diseases (eg, rheumatoid arthritis, systemic sclerosis), familial disease, asbestosis, and certain drug-induced lung diseases (",
"    <a class=\"graphic graphic_table graphicRef57228 \" href=\"UTD.htm?1/7/1147\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Hermansky-Pudlak syndrome, an autosomal recessive disorder characterized by oculocutaneous albinism and platelet abnormalities, is a rare cause of UIP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/30\">",
"     30",
"    </a>",
"    ]. The UIP pattern of fibrosis has also been described in chronic hypersensitivity pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distinguishing the idiopathic form of UIP from lesions complicating the use of certain drugs is largely a matter of correlation with the clinical information. Familial IPF has no distinct distinguishing features and requires a thorough family history. A diagnosis of asbestosis requires not only an appropriate occupational history but also demonstration of asbestos fibers (usually in the form of ferruginated asbestos bodies) in the tissue specimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of even rare poorly formed granulomas or giant cells in the interstitium should raise suspicion for chronic hypersensitivity pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of UIP frequently includes the other idiopathic interstitial pneumonias, hypersensitivity pneumonitis, and pulmonary Langerhans' cell histiocytosis (also referred to as Langerhans' cell granulomatosis, pulmonary eosinophilic granuloma, and pulmonary histiocytosis X) (",
"    <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DESQUAMATIVE INTERSTITIAL PNEUMONIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desquamative interstitial pneumonia (DIP) is a distinct clinicopathologic entity that differs substantially from UIP (",
"    <a class=\"graphic graphic_table graphicRef65643 \" href=\"UTD.htm?36/7/36987\">",
"     table 7",
"    </a>",
"    ). It is relatively uncommon, comprising 8 percent of biopsied Mayo Clinic patients suspected of having IPF, less than 3 percent of interstitial lung disease biopsies at National Jewish Medical and Research Center in Denver, Colorado, and 16 percent of patients in a series from the Pulmonary Branch of the United States National Heart, Lung and Blood Institute [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DIP typically affects cigarette smokers in their fourth or fifth decades of life. While the vast majority (&gt;90 percent) of patients with DIP are smokers, a small percentage of cases are associated with connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/33\">",
"     33",
"    </a>",
"    ]. Physiologic testing usually shows mild reduction in lung volumes associated with a moderate decrease in diffusing capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiographic abnormalities tend to be less severe than those seen in UIP; indeed, chest radiographs are normal in as many as one-fifth of patients. HRCT shows ground glass opacities without the peripheral reticular and reticulonodular opacities characteristic of UIP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80527 \" href=\"UTD.htm?24/28/25024\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/35\">",
"     35",
"    </a>",
"    ]. One review of HRCT findings found no evidence of progression from DIP to UIP, further supporting the concept that DIP and UIP are separate and distinct entities, with important differences in prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIP differs histologically from UIP in that the changes tend to be much more uniform at low magnification and lack the variegated appearance typical of UIP (",
"    <a class=\"graphic graphic_table graphicRef59081 \" href=\"UTD.htm?15/24/15755\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58789 \" href=\"UTD.htm?19/9/19608\">",
"     picture 1",
"    </a>",
"    ). The alveolar septa are lined by plump cuboidal pneumocytes and thickened by a sparse inflammatory infiltrate that often includes plasma cells and occasional eosinophils. There is usually minimal or mild associated fibrosis without honeycomb changes. The most striking feature is the presence of numerous mononuclear cells within most of the distal air spaces. These mononuclear cells represent smokers' macrophages rather than desquamated pneumocytes, as had been originally proposed. The smokers' macrophage is characterized by finely granular brown pigment flecked with tiny black particles. These changes overlap with those described in so-called respiratory bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation is an important component of the management of DIP, although the exact impact of smoking cessation is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/39\">",
"     39",
"    </a>",
"    ]. Some patients have improved with smoking cessation alone, but others have progressed despite cessation of smoking. Glucocorticoids have been reported to be beneficial in case series, although improvement may be temporary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. In a systematic review of reported cases of DIP, approximately 50 percent improved with smoking cessation and systemic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/40\">",
"     40",
"    </a>",
"    ]. A few patients have been treated with additional immunosuppressive agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , although the response to these agents is not described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/40\">",
"     40",
"    </a>",
"    ]. The overall survival is 70 to 88 percent after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/33,39,40\">",
"     33,39,40",
"    </a>",
"    ]. Several studies have demonstrated 100 percent survival rates for DIP, but to some extent this reflects a trend toward excluding patients with associated fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RESPIRATORY BRONCHIOLITIS-ASSOCIATED ILD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) and DIP share several overlapping clinicopathologic features, and both have a better prognosis than UIP. Like DIP, RB-ILD is an uncommon form of interstitial pneumonia, accounting for only 2 percent of biopsied Mayo Clinic patients who were suspected of having IPF. DIP and RB-ILD show significant clinical, radiologic and histologic overlap, and in some patients the distinction is arbitrary and of uncertain clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory bronchiolitis was defined in 1974 as a distinct histopathologic entity characterized by the presence of pigmented intraluminal macrophages within first and second-order respiratory bronchioles. Investigators hypothesized that respiratory bronchiolitis might contribute to small airways dysfunction in cigarette smokers. The histopathologic finding of respiratory bronchiolitis has been linked to a syndrome of diffuse interstitial lung disease (respiratory bronchiolitis-associated interstitial lung disease or RB-ILD) that can mimic IPF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34633?source=see_link\">",
"     \"Respiratory bronchiolitis-associated interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of RB-ILD are nonspecific. RB-ILD typically occurs during the fourth or fifth decades of life and almost always affects current smokers with average exposures of over 30 pack-years of cigarette smoking (",
"    <a class=\"graphic graphic_table graphicRef68326 \" href=\"UTD.htm?41/34/42539\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/42\">",
"     42",
"    </a>",
"    ]. Men are affected more often than women by a ratio of almost 2:1. Symptoms are usually mild and not disabling. Nearly all patients present with nonspecific respiratory complaints; these include the insidious onset of dyspnea and a new or changed cough. Chest radiographs are abnormal in 80 percent of patients and show diffuse fine reticular or reticulonodular opacities in a bibasilar distribution (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68487 graphicRef82553 \" href=\"UTD.htm?15/6/15461\">",
"     image 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to previous reports, the largest series of RB-ILD patients suggests that RB-ILD is not a benign disease and that symptoms and physiology improve in only a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/43\">",
"     43",
"    </a>",
"    ]. However, this study did confirm that prolonged survival is most common and that death secondary to progressive ILD is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory bronchiolitis is defined by the presence of pigmented macrophages within the lumen of respiratory bronchioles (",
"    <a class=\"graphic graphic_table graphicRef73463 \" href=\"UTD.htm?5/11/5307\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57687 \" href=\"UTD.htm?10/51/11065\">",
"     picture 2",
"    </a>",
"    ). The changes are patchy at low magnification and have a bronchiolocentric distribution. Respiratory bronchioles, alveolar ducts, and peribronchiolar alveolar spaces contain clusters of dusty brown macrophages. The lightly pigmented cells have abundant cytoplasm that contains finely granular golden brown particles. The cytoplasmic particles are PAS-positive and also stain with Prussian blue. Positive staining with Prussian blue, an iron stain, correlates with observations of increased iron content in alveolar macrophages from cigarette smokers.",
"   </p>",
"   <p>",
"    Intraluminal macrophages are accompanied by a patchy submucosal and peribronchiolar infiltrate of lymphocytes and histiocytes. The interstitial histiocytes may contain dusty brown cytoplasmic pigment identical to that seen within the intraluminal macrophages, or they may contain coarse black anthracotic pigment. Peribronchiolar fibrosis is also seen and expands contiguous alveolar septa, which are lined by hyperplastic type 2 cells and cuboidal bronchiolar-type epithelium. The combination of alveolar septal thickening, epithelial hyperplasia, and pigmented intraluminal macrophages mimics the appearance of DIP.",
"   </p>",
"   <p>",
"    The intraluminal macrophages in DIP usually contain dusty brown pigment identical to that seen in RB-ILD and show the same positive staining reactions with PAS and Prussian blue. The main feature that distinguishes DIP from RB-ILD is that DIP affects the lung in a more uniform and diffuse manner, lacking the bronchiolocentric distribution seen in RB-ILD, but there is considerable clinical, radiologic, and histologic overlap between these entities. It is likely that DIP and RB-ILD are highly related if not identical lesions, differing only in the severity and extent of the abnormality (ie, RB-ILD =",
"    <span class=\"nowrap\">",
"     mild/early",
"    </span>",
"    DIP). For that reason it has been suggested that all cases be grouped under the heading of RB-ILD, avoiding the historically entrenched but descriptively inaccurate term of \"desquamative\" interstitial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of RB-ILD includes a number of interstitial lung diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peribronchiolar fibrosis coupled with hyperplasia of peribronchiolar epithelium may mimic the appearance of UIP. UIP differs from RB-ILD in that the interstitial changes are more peripherally situated and include alternating areas of inflammation, fibrosis, and honeycomb change, imparting a variegated appearance to the tissue at low magnification. In contrast, fibrosis is mild in RB-ILD, and honeycomb change does not occur.",
"     </li>",
"     <li>",
"      Pulmonary Langerhans' cell histiocytosis (eosinophilic granuloma, Langerhans' granulomatosis) is frequently associated with a \"DIP-like\" reaction and also can resemble RB-ILD. At low magnification, however, pulmonary Langerhans' cell histiocytosis is a predominantly interstitial lesion characterized by the presence of centrally scarred stellate nodules containing a polymorphic inflammatory infiltrate. Diagnosis of eosinophilic granuloma is predicated on recognition of characteristic Langerhans' cells within the inflammatory infiltrate in the appropriate histological context. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage is also characterized by the presence of pigment-laden macrophages and can be confused with RB-ILD. Low magnification examination is helpful in distinguishing these conditions because the pigmented macrophages have a bronchiolocentric distribution in RB-ILD, as opposed to a more diffuse and random distribution in pulmonary hemorrhage. Other histological clues are often present in alveolar hemorrhage syndromes, including the presence of intraalveolar erythrocytes with associated fibrin, and areas of organization resembling organizing pneumonia. The pigment in RB-ILD, like the pigment in DIP and \"DIP-like\" reactions, is finely dispersed and indistinct, imparting a dusty appearance to the cells. In contrast, hemosiderin pigment in pulmonary hemorrhage forms large, coarse, refractile granules that often have a",
"      <span class=\"nowrap\">",
"       yellow/gold",
"      </span>",
"      hue. Both pigments stain positively with Prussian blue, but hemosiderin stains more brightly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither RB-ILD nor DIP should be viewed as free standing histopathologic entities, since areas resembling both are common as incidental findings in cigarette smokers. Given the dangers of sampling bias, RB-ILD and DIP should be diagnosed only when other forms of interstitial lung disease have been vigorously excluded, a process that requires correlation of biopsy findings with clinical and radiographic features. A review identified respiratory bronchiolitis in 109 of 156 consecutive surgical specimens; \"DIP-like\" areas were identified in 6. Only two (1.8 percent) patients were thought to have either RB-ILD (1) or DIP (1) after careful correlation with clinical, radiologic and pathologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23179520\">",
"    <span class=\"h1\">",
"     SMOKING-RELATED INTERSTITIAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical interstitial lung abnormalities (ILA) appear common in smokers and these findings do not meet criteria for usual interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease, or pulmonary Langerhans histiocytosis. On high resolution computed tomography (HRCT), subclinical ILA are associated with parenchymal nodules with relatively low attenuation, ground-glass opacities, subpleural micronodules, and dependent areas of increased attenuation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/44-49\">",
"     44-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These radiographic findings have not been closely examined histopathologically. However, studies of lobectomy specimens from smokers without clinically defined interstitial lung disease have shown varying degrees of airspace enlargement and alveolar septal widening with collagen deposition, but without the temporal heterogeneity or fibroblast foci typical of UIP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The histopathologic findings of smoking-related ILA appear to be distinct from combined pulmonary fibrosis (UIP) and emphysema (known as CPFE) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/45,46,52,53\">",
"     45,46,52,53",
"    </a>",
"    ], but may overlap with those of emphysematous airspace enlargement with associated interstitial fibrosis sometimes seen in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Other authors have described similar smoking related interstitial abnormalities that they termed respiratory bronchiolitis-associated interstitial lung disease (RBILD) with fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ACUTE INTERSTITIAL PNEUMONIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the idiopathic interstitial pneumonias are chronic processes characterized by an insidious onset and a relentlessly progressive course. In contrast, acute interstitial pneumonia (AIP) presents with the explosive onset of respiratory symptoms and is characterized by rapidly progressive respiratory failure associated with diffuse opacities on chest radiographs. This acute variant is analogous to the acute respiratory distress syndrome (ARDS), differing only in that it is not preceded by a catastrophic event (ie, the condition is idiopathic). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other terms have been proposed for this clinicopathological syndrome, including Hamman-Rich syndrome and accelerated interstitial pneumonia. Regardless of the terminology, the important point is that AIP should be distinguished from the group of chronic interstitial pneumonias because of marked differences in natural history. AIP has the same poor prognosis as ARDS, and the majority of patients die of respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link\">",
"     \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, AIP is identical to the organizing or proliferative stage of diffuse alveolar damage (DAD) (",
"    <a class=\"graphic graphic_table graphicRef81916 \" href=\"UTD.htm?13/49/14107\">",
"     table 11",
"    </a>",
"    ). The main finding is extensive interstitial fibroblast proliferation within an edematous-appearing stroma (",
"    <a class=\"graphic graphic_picture graphicRef53033 \" href=\"UTD.htm?14/18/14633\">",
"     picture 3",
"    </a>",
"    ). Alveolar septa are dramatically thickened and are lined by hyperplastic type II pneumocytes that are often cytologically atypical. Hyaline membrane remnants are inconspicuous but may be present within occasional air spaces or within alveolar walls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main differential diagnosis in the setting of idiopathic interstitial lung disease in a non-immunocompromised patient is so-called accelerated IPF. The distinction depends not only on recognizing underlying UIP, but also on correlation with the clinical and radiographic findings. In a comparison of patients with AIP and patients suffering acute exacerbation of IPF reported only in abstract form, patients with accelerated IPF were older, more likely to have digital clubbing, and had radiographic features of UIP on HRCT scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONSPECIFIC INTERSTITIAL PNEUMONIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific interstitial pneumonia is a pathologic description of a chronic interstitial pneumonia that lacks the histopathologic features typical of UIP, DIP, RB-ILD or AIP (",
"    <a class=\"graphic graphic_table graphicRef60068 \" href=\"UTD.htm?0/51/827\">",
"     table 12",
"    </a>",
"    ). These lesions are often characterized by a relatively uniform appearance at low magnification due to a cellular interstitial infiltrate of mononuclear inflammatory cells associated with varying degrees of interstitial fibrosis. Examples of this condition have undoubtedly been included in studies of idiopathic pulmonary fibrosis as \"early\" or \"cellular\" UIP. In a retrospective review of patients suspected of having IPF, 14 percent had NSIP, making it the second most common histological category [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important clinical characteristics that distinguish NSIP from UIP are a subacute rather than insidious onset of symptoms, associated fever in about one-third of patients, lack of a strong male predominance, relative absence of clubbing in NSIP, and increased frequency of features suggestive of connective tissue disease.",
"   </p>",
"   <p>",
"    A more detailed discussion of the clinical manifestations, risk factors, prognosis, evaluation, and treatment of NSIP is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the term implies, the histological findings in patients with NSIP are variable (",
"    <a class=\"graphic graphic_table graphicRef81034 \" href=\"UTD.htm?19/8/19596\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The main change in all cases is an interstitial pneumonia characterized by expansion of alveolar septa by a variably dense infiltrate of predominantly mononuclear inflammatory cells with or without associated fibrosis. As with any interstitial pneumonia, there is the usual range of associated nonspecific secondary changes, including epithelial hyperplasia and some airspace organization.",
"   </p>",
"   <p>",
"    NSIP can be divided into three groups based upon the presence and degree of interstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/62\">",
"     62",
"    </a>",
"    ]. The majority of patients had a prominent inflammatory component either without (Group I) or with (Group II) concomitant fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef75438 \" href=\"UTD.htm?27/22/28008\">",
"     picture 4",
"    </a>",
"    ). Biopsies showing predominantly fibrosis (Group III) were the least common (9 of 64 patients) but accounted for a disproportionate number of patients (2 of 5) who died of their disease (",
"    <a class=\"graphic graphic_picture graphicRef58583 \" href=\"UTD.htm?43/22/44392\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As noted in other studies, the most compelling distinction between NSIP and UIP was related to outcome: NSIP had a significantly better prognosis than UIP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Nearly 75 percent of patients with NSIP improved or recovered, versus none of the patients with UIP. All of the patients with NSIP who suffered a more aggressive course were in the fibrotic subset.",
"   </p>",
"   <p>",
"    The fibrotic changes noted in patients with fibrotic NSIP have the same peripheral subpleural distribution as that typically seen in UIP, but differ in that they are more temporally homogeneous in contrast to the variegated pattern typical of UIP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. These observations raise the possibility that some patients with fibrotic NSIP may in fact have UIP that is not fully appreciated in the lung biopsies.",
"   </p>",
"   <p>",
"    It should be noted that focal areas of organizing pneumonia (also called bronchiolitis obliterans organizing pneumonia or BOOP) resembling the changes seen in the syndrome of idiopathic organizing pneumonia are a common finding. NSIP differs from classical organizing",
"    <span class=\"nowrap\">",
"     pneumonia/BOOP,",
"    </span>",
"    however, in that \"BOOP-like\" areas represent less than 10 percent of the cross-sectional area of the lesional tissue and are overshadowed by the interstitial pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential difficulty in separating fibrotic forms of NSIP from UIP was also highlighted in a study of explanted specimens from transplant recipients who had undergone previous surgical lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/23/4474/abstract/66\">",
"     66",
"    </a>",
"    ]. Areas resembling NSIP are common as a nonspecific finding in cases of otherwise typical UIP. The key features important in accurately separating NSIP and UIP include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patchy involvement and fibrosis characterized by abrupt transitions resulting in a patchwork pattern",
"     </li>",
"     <li>",
"      Architectural distortion that included honeycomb change",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interstitial scarring",
"     </li>",
"     <li>",
"      Fibroblast foci",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these features taken on its own is diagnostic, but the three together excludes a diagnosis of NSIP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LYMPHOID INTERSTITIAL PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid interstitial pneumonia (also known as lymphocytic interstitial pneumonia or LIP) is one entity within a spectrum of lymphoproliferative disorders that can involve the lung. LIP is an uncommon histopathologic entity characterized by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=see_link\">",
"     \"Lymphoid interstitial pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18086225\">",
"    <span class=\"h1\">",
"     CRYPTOGENIC ORGANIZING PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic organizing pneumonia (COP), which is the name applied to the idiopathic form of organizing pneumonia (idiopathic BOOP), is a distinct clinical entity with features of an inflammatory pneumonia rather than a primary airway disorder. The histopathologic findings characteristic of cryptogenic organizing pneumonia (COP) include excessive proliferation of granulation tissue within small airways (proliferative bronchiolitis) and alveolar ducts, associated with chronic inflammation in the surrounding alveoli. COP is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=see_link\">",
"       \"Patient information: Idiopathic pulmonary fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The idiopathic interstitial pneumonias are a subset of diffuse interstitial lung diseases of unknown etiology characterized by expansion of the interstitial compartment (ie, that portion of the lung parenchyma sandwiched between the epithelial and endothelial basement membranes) with an infiltrate of inflammatory cells. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The idiopathic interstitial pneumonias are classified based on their histopathologic appearances, as outlined in a joint American Thoracic Society and European Respiratory Society statement (",
"      <a class=\"graphic graphic_table graphicRef68251 \" href=\"UTD.htm?23/25/23963\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histologic hallmark and chief diagnostic criterion for usual interstitial pneumonia (UIP) is a heterogeneous appearance with alternating areas of normal lung, interstitial inflammation, fibroblast foci, and honeycomb change. UIP is the most specific form of the idiopathic interstitial pneumonias and can be defined based on its morphologic features alone. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Usual interstitial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desquamative interstitial pneumonia (DIP) differs histologically from UIP in that the changes tend to be much more uniform at low magnification and lack the variegated appearance typical of UIP (",
"      <a class=\"graphic graphic_table graphicRef59081 \" href=\"UTD.htm?15/24/15755\">",
"       table 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58789 \" href=\"UTD.htm?19/9/19608\">",
"       picture 1",
"      </a>",
"      ). The most striking feature is the presence of numerous mononuclear cells (smokers' macrophages) within most of the distal air spaces. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Desquamative interstitial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key histopathologic feature of respiratory bronchiolitis-associated interstitial lung disease (RBILD) is the presence of pigmented macrophages within the lumen of respiratory bronchioles (",
"      <a class=\"graphic graphic_table graphicRef73463 \" href=\"UTD.htm?5/11/5307\">",
"       table 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57687 \" href=\"UTD.htm?10/51/11065\">",
"       picture 2",
"      </a>",
"      ). The main feature that distinguishes DIP from RB-ILD is that DIP affects the lung in a more uniform and diffuse manner and lacks the bronchiolocentric distribution seen in RB-ILD. However, considerable clinical, radiologic, and histologic overlap exists between these entities. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Respiratory bronchiolitis-associated ILD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute interstitial pneumonia (AIP) presents with the explosive onset of respiratory symptoms and is characterized by rapidly progressive respiratory failure. Histologically, AIP is identical to the organizing or proliferative stage of diffuse alveolar damage (DAD) (",
"      <a class=\"graphic graphic_table graphicRef81916 \" href=\"UTD.htm?13/49/14107\">",
"       table 11",
"      </a>",
"      ). The main finding is extensive interstitial fibroblast proliferation within an edematous-appearing stroma (",
"      <a class=\"graphic graphic_picture graphicRef53033 \" href=\"UTD.htm?14/18/14633\">",
"       picture 3",
"      </a>",
"      ). When AIP complicates underlying UIP, the process is called &ldquo;accelerated IPF&rdquo;. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute interstitial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histological findings in patients with nonspecific interstitial pneumonia (NSIP) are variable (",
"      <a class=\"graphic graphic_table graphicRef81034 \" href=\"UTD.htm?19/8/19596\">",
"       table 13",
"      </a>",
"      ). The main change in all cases is an interstitial pneumonia characterized by expansion of alveolar septa by a variably dense infiltrate of predominantly mononuclear inflammatory cells with or without associated fibrosis. NSIP can be considered &ldquo;cellular&rdquo; in the absence of fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef75438 \" href=\"UTD.htm?27/22/28008\">",
"       picture 4",
"      </a>",
"      ), &ldquo;fibrosing&rdquo; when fibrosis is prominent (",
"      <a class=\"graphic graphic_picture graphicRef58583 \" href=\"UTD.htm?43/22/44392\">",
"       picture 5",
"      </a>",
"      ), and &ldquo;cellular with concomitant fibrosis&rdquo; when the picture is mixed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonspecific interstitial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphoid interstitial pneumonia (LIP) is an uncommon histopathologic entity characterized by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Lymphoid interstitial pneumonia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=see_link\">",
"       \"Lymphoid interstitial pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The histopathologic lesions characteristic of cryptogenic organizing pneumonia (COP) include excessive proliferation of granulation tissue within small airways (proliferative bronchiolitis) and alveolar ducts, associated with chronic inflammation in the surrounding alveoli. (See",
"      <a class=\"local\" href=\"#H18086225\">",
"       'Cryptogenic organizing pneumonia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      UIP is the most specific form of the idiopathic interstitial pneumonias and can be defined based on its morphologic features alone. Histologic patterns of DIP, RB-ILD, DAD, and NSIP require careful correlation with clinical and radiologic data before considering individual cases to be idiopathic.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/1\">",
"      Liebow, A. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 1975; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/2\">",
"      Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/3\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/4\">",
"      Nicholson AG. Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup. Histopathology 2002; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/5\">",
"      Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/6\">",
"      American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/7\">",
"      Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/8\">",
"      Fern&aacute;ndez P&eacute;rez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/9\">",
"      Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/10\">",
"      Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/11\">",
"      Quadrelli S, Molinari L, Ciallella L, et al. Radiological versus histopathological diagnosis of usual interstitial pneumonia in the clinical practice: does it have any survival difference? Respiration 2010; 79:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/12\">",
"      Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/13\">",
"      Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008; 177:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/14\">",
"      Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/15\">",
"      Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008; 177:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/16\">",
"      Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/17\">",
"      Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/18\">",
"      Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/19\">",
"      Akira M, Hamada H, Sakatani M, et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/20\">",
"      Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/21\">",
"      Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008; 32:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/22\">",
"      Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007; 131:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/23\">",
"      Cool CD, Groshong SD, Rai PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 2006; 174:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/24\">",
"      Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/25\">",
"      Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/26\">",
"      Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/27\">",
"      King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/28\">",
"      Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/29\">",
"      Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/30\">",
"      Suzuki T, Li W, Zhang Q, et al. Hermansky-Pudlak syndrome is caused by mutations in HPS4, the human homolog of the mouse light-ear gene. Nat Genet 2002; 30:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/31\">",
"      Sahin H, Brown KK, Curran-Everett D, et al. Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival. Radiology 2007; 244:591.",
"     </a>",
"    </li>",
"    <li>",
"     King TE Jr, Schwarz MI. Chronic diffuse parenchymal lung disease. In: Medical management of pulmonary diseases, Davis G (Ed), Marcel Decker, New York 1999. p.487.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/33\">",
"      Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/34\">",
"      Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis 1987; 135:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/35\">",
"      Akira M, Yamamoto S, Hara H, et al. Serial computed tomographic evaluation in desquamative interstitial pneumonia. Thorax 1997; 52:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/36\">",
"      Hartman TE, Primack SL, Kang EY, et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT. Chest 1996; 110:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/37\">",
"      Moon J, du Bois RM, Colby TV, et al. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax 1999; 54:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/38\">",
"      Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989; 64:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/39\">",
"      Ryu JH, Myers JL, Capizzi SA, et al. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest 2005; 127:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/40\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     Myers, JL. Respiratory bronchiolitis-associated interstitial lung disease. In: Diseases of the Bronchioles, Epler, G (Eds), Raven Press, New York 1994. p.297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/42\">",
"      Fraig M, Shreesha U, Savici D, Katzenstein AL. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am J Surg Pathol 2002; 26:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/43\">",
"      Portnoy J, Veraldi KL, Schwarz MI, et al. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest 2007; 131:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/44\">",
"      Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/45\">",
"      Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 2011; 66:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/46\">",
"      Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010; 188:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/47\">",
"      Lederer DJ, Enright PL, Kawut SM, et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med 2009; 180:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/48\">",
"      Tsushima K, Sone S, Yoshikawa S, et al. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med 2010; 104:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/49\">",
"      Doyle TJ, Washko GR, Fernandez IE, et al. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med 2012; 185:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/50\">",
"      Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 2010; 41:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/51\">",
"      Kawabata Y, Hoshi E, Murai K, et al. Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course. Histopathology 2008; 53:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/52\">",
"      Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011; 38:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/53\">",
"      Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/54\">",
"      The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 1985; 132:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/55\">",
"      Churg A, M&uuml;ller NL, Wright JL. Respiratory bronchiolitis/interstitial lung disease: fibrosis, pulmonary function, and evolving concepts. Arch Pathol Lab Med 2010; 134:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/56\">",
"      Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. Mod Pathol 2006; 19:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/57\">",
"      Olson J, Colby TV, Elliott CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/58\">",
"      Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/59\">",
"      Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/60\">",
"      Cottin V, Donsbeck AV, Revel D, et al. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/61\">",
"      Katzenstein AL, Myers JL. Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria. Am J Surg Pathol 2000; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/62\">",
"      Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/63\">",
"      Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/64\">",
"      Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/65\">",
"      Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/23/4474/abstract/66\">",
"      Katzenstein AL, Zisman DA, Litzky LA, et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002; 26:1567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4302 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4474=[""].join("\n");
var outline_f4_23_4474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      USUAL INTERSTITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DESQUAMATIVE INTERSTITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RESPIRATORY BRONCHIOLITIS-ASSOCIATED ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23179520\">",
"      SMOKING-RELATED INTERSTITIAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ACUTE INTERSTITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONSPECIFIC INTERSTITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LYMPHOID INTERSTITIAL PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18086225\">",
"      CRYPTOGENIC ORGANIZING PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4302|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/30/43502\" title=\"algorithm 1\">",
"      Classification diffuse lung dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/32/4623\" title=\"algorithm 2\">",
"      Diagnostic evaluation of DPLD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4302|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/4/21569\" title=\"diagnostic image 1\">",
"      UIP IPF radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/28/25024\" title=\"diagnostic image 2\">",
"      DIP CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/9/40095\" title=\"diagnostic image 3A\">",
"      RB ILD CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/46/2785\" title=\"diagnostic image 3B\">",
"      RB ILD CT II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4302|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/9/19608\" title=\"picture 1\">",
"      DIP histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/51/11065\" title=\"picture 2\">",
"      RB-ILD histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14633\" title=\"picture 3\">",
"      Hamman Rich High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/22/28008\" title=\"picture 4\">",
"      Cellular NSIP histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/22/44392\" title=\"picture 5\">",
"      Fibrosing NSIP histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4302|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/10/10412\" title=\"table 1\">",
"      Previous classification IIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/25/23963\" title=\"table 2\">",
"      Histologic clinical class idiopathic interstitial pneumonias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/15/253\" title=\"table 3\">",
"      Radiologic Ddx IIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/53/41819\" title=\"table 4\">",
"      ATS ERS Dx Criteria IPF without Bx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/13/16603\" title=\"table 5\">",
"      Histologic features UIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/7/1147\" title=\"table 6\">",
"      Clinical conditions UIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/7/36987\" title=\"table 7\">",
"      Comparison of UIP and DIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/24/15755\" title=\"table 8\">",
"      Histologic features DIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/34/42539\" title=\"table 9\">",
"      Clinical findings in RBILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/11/5307\" title=\"table 10\">",
"      Histologic features RB-ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/49/14107\" title=\"table 11\">",
"      Histologic features of diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/51/827\" title=\"table 12\">",
"      Clinical setting NSIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/8/19596\" title=\"table 13\">",
"      Histologic features NSIP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/409?source=related_link\">",
"      Lymphoid interstitial pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32378?source=related_link\">",
"      Pathogenesis of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=related_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34633?source=related_link\">",
"      Respiratory bronchiolitis-associated interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_23_4475="MDI with spacer technique";
var content_f4_23_4475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technique for use of MDI with spacer or valved holding chamber",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Warm MDI canister to body temperature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assemble apparatus and check for loose objects in the device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shake canister vigorously",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold canister in vertical position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe out normally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place holding chamber in mouth, or place mask completely over nose and mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage patient to breathe through mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in slowly and actuate MDI once at the beginning of inspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allow about 15-30 seconds between actuations, or long enough to perform each inhalation properly",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4475=[""].join("\n");
var outline_f4_23_4475=null;
var title_f4_23_4476="Symptoms CMV mononucleosis";
var content_f4_23_4476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs in nine patients with spontaneous cytomegalovirus mononucleosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malaise",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chills",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myalgia",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sore throat",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Headache",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anorexia",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal pain",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pharyngeal erythema",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphadenopathy",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rash*",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Splenomegaly",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exudative pharyngitis",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes one patient whose rash was associated with ampicillin therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Jordan, MC, Rousseau, W, Stewart, JA, et al. Spontaneous cytomegalovirus mononucleosis. Clinical and laboratory observations in nine cases. Ann Intern Med 1973; 79:153.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4476=[""].join("\n");
var outline_f4_23_4476=null;
var title_f4_23_4477="Excretion patterns";
var content_f4_23_4477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Excretion patterns for porphyrins and porphyrin precursors and other laboratory findings in the human porphyrias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Porphyria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Urine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stool",
"       </td>",
"       <td class=\"subtitle1\">",
"        Erythrocytes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADP",
"       </td>",
"       <td>",
"        ALA, coproporphyrin III",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        Zinc protoporphyrin",
"       </td>",
"       <td>",
"        ALA*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIP",
"       </td>",
"       <td>",
"        ALA, PBG, uroporphyrin",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        Decreased PBGD activity (most cases)",
"        <sup>",
"         *",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         ALA, PBG*",
"        </p>",
"        <p>",
"         [~620 nm]",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CEP",
"       </td>",
"       <td>",
"        Uroporphyrin I; coproporphyrin I",
"       </td>",
"       <td>",
"        Coproporphyrin I",
"       </td>",
"       <td>",
"        Uroporphyrin I; coproporphyrin I",
"       </td>",
"       <td>",
"        <p>",
"         Uroporphyrin I, coproporphyrin I",
"        </p>",
"        <p>",
"         [~620 nm]",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCT and HEP",
"       </td>",
"       <td>",
"        Uroporphyrin, heptacarboxyl porphyrin",
"       </td>",
"       <td>",
"        Heptacarboxyl porphyrin, isocoproporphyrins",
"       </td>",
"       <td>",
"        Zinc protoporphyrin (in HEP)",
"       </td>",
"       <td>",
"        <p>",
"         Uroporphyrin, heptacarboxyl porphyrin",
"        </p>",
"        <p>",
"         [~620 nm]",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCP",
"       </td>",
"       <td>",
"        ALA, PBG, coproporphyrin III",
"       </td>",
"       <td>",
"        Coproporphyrin III",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        <p>",
"         &Delta;",
"        </p>",
"        <p>",
"         [~620 nm]",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VP",
"       </td>",
"       <td>",
"        ALA, PBG, coproporphyrin III",
"       </td>",
"       <td>",
"        Coproporphyrin III, protoporphyrin",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        <p>",
"         Porphyrin-peptide conjugate",
"        </p>",
"        <p>",
"         [~626 to 628 nm]",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EPP",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        Protoporphyrin*",
"       </td>",
"       <td>",
"        Free protoporphyrin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Protoporphyrin",
"        </p>",
"        <p>",
"         [~634 nm]",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; CEP: congenital erythropoietic porphyria; PCT: porphyria cutanea tarda; HEP: hepatoerythropoietic porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; EPP: erythropoietic protoporphyria; ALA: delta-aminolevulinic acid; PBG: porphobilinogen; PBGD: porphobilinogen deaminase; XLPP: X-linked protoporphyria.",
"     <br>",
"      <font class=\"bullet\">",
"       *",
"      </font>",
"      &nbsp;Porphyrin levels normal or slightly increased.",
"      <br>",
"       &bull;&nbsp;Fluorescence emission peak of diluted plasma at neutral pH.",
"       <br>",
"        &Delta;&nbsp;Plasma porphyrins usually normal, but increased when blistering skin lesions develop.",
"        <br>",
"         &loz;&nbsp;Urine porphyrins (especially coproporphyrin) increase only with hepatopathy.",
"         <br>",
"          &sect;&nbsp;Zinc protoporphyrin &le;5 percent of total in classic EPP, but 15 to 50 percent in variant form (XLPP).",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Karl Anderson, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4477=[""].join("\n");
var outline_f4_23_4477=null;
var title_f4_23_4478="Nighttime serum melatonin";
var content_f4_23_4478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Nighttime peak serum melatonin levels in subjects of different ages, years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 393px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhdanova, IV, Wurtman, RJ. In: Endocrinology: Basic and Clinical Principles, PM, Conn, S, Melmed (Eds), Humana Press, Inc, Totowa, NJ, 1997. p. 281. Copyright &copy; 1997 Humana Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4478=[""].join("\n");
var outline_f4_23_4478=null;
var title_f4_23_4479="Autosomal dominant--pedigree";
var content_f4_23_4479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of an autosomal dominant pedigree showing complete penetrance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AVEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuCuvi74Mtr26tZNRummtpnt5RHptzIqujFWG5YyDggjg0Ad7RXn3/C4fBf/P8A3/8A4Kbv/wCNUknxk8ExozyajfIijczNpV2AAOpJ8qgD0KiorS4hvLWG5tZFlt5kWSORTkMpGQR7EGpaACiiuP8AHXxJ8KeB0x4i1aGC4K7ktY8yTNxkfIvIz6nA96AOworyfwx8f/h/r98LRNUksJmIVDfxGJHJz/Fyo6fxEdRXq6OrorowZGGQQcgj1oAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4L4Nf8i9rH/Ye1P8A9KpK72uC+DX/ACL2sf8AYe1P/wBKpKAO9rm/iZ/yTjxX/wBgm7/9EvXSVzfxM/5Jx4r/AOwTd/8Aol6AJfh9/wAiD4a/7Blt/wCilrfryjwV8L/DV74N0G5mXV/NmsLeR9ur3ajJjUnAEmAOeg4rH8M+AtFvviR410m5k1h7HTUsDbR/2vdDYZI3Z+RJk5IHWgD0P4q+K08E+AdY107TNbxbYFOPmlY7UHPXkgn2Br85db1W+1zVbnUtWuZLq+uXMksshyWJ/wA9O1fZ3xw+Emmf8Kx1mfQF1Nr+1QXKpLqNxOrqhBcbHkK525PTPHFfEdABX1x+x58QrzU4rzwhq9y85tIRPYNIQSsYIDR56kDKkdcDPTAr5Hr6J/Yt0K6ufHWp62FZbKyszAz44aSRlwv5Kx/L1FAH2XRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeReGLrxt4UTVrCHwHPqMEmq3l3FcpqltGHSWZnU7WbI4I6167RQB55/wl/jn/omd3/4ObT/AOKrL8U65471vwxrGlJ8OLqF76zmtRIdYtCELoVzjdzjNer0UAZHg6yn03wjodjeJ5dzbWMEMqZB2usagjI4PINcj4K/5LH8Sf8Arnpf/omSvRa868Ff8lk+JX/XPS//AETJQB6IwDKVYAg8EHvXzV8VP2ZYNX1G41TwReQWEkzF30+cEQ5x/wAs2GSuT2IxzxjGK+lqKAPjXw1+yv4lub9R4h1TTrGyBG5rZmmkYc/dBAA7dT379K+qvAvhHSPBPh230bQrcRW0Qyznl5n7u57sf/rDAAFdBRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXBeNNa8Tr420jw/4Ul0iBrqxuLyWXUIJJR+7eNQFCOuP9Z+lR/ZPil/0FvB3/gvuP/jtAHoNFeffZPil/wBBfwd/4L7j/wCO0fZPil/0F/B3/gvuP/jtAHoNFeffZPil/wBBfwd/4L7j/wCO0fZPil/0F/B3/gvuP/jtAHoNFeffZPil/wBBfwd/4L7j/wCO0fZPil/0F/B3/gvuP/jtAHoNFeT+L9R+J3hrwvqmtTah4QnjsLd7hoksLgFwozgHza1IIPijNBHKNW8HAOobH9n3HGR/11oA9Eorz/7J8Uv+gv4O/wDBfcf/AB2j7J8Uv+gv4O/8F9x/8doA9Aorz/7J8Uf+gv4O/wDBfcf/AB2j7J8Uf+gv4O/8F9x/8eoA9Aorz/7J8Uf+gv4O/wDBfcf/AB6j7J8Uf+gv4O/8F9x/8eoA9ArzrwV/yWT4lf8AXPS//RMlS/ZPij/0F/B3/gvuP/j1cP4Ut/iA3xQ8eLa6l4ZXUFTT/tbyWU5jYeU+zYBJkYGc5JyemKAPeKK8/wDsnxR/6C/g7/wX3H/x6j7J8Uf+gv4O/wDBfcf/AB6gD0CivP8A7J8Uf+gv4O/8F9x/8eo+yfFH/oL+Dv8AwX3H/wAeoA9Aorz/AOyfFL/oLeDv/Bfcf/HaPsnxS/6C3g7/AMF9x/8AHaAPQKK8/wDsnxS/6C/g7/wX3H/x2sTX9V+JujanoNlJqHhGVtWuzaIy2FwBGRE8mT+95GEI/GgD1uivP/snxS/6C/g7/wAF9x/8do+yfFL/AKC/g7/wX3H/AMdoA9Aorz77J8Uv+gv4O/8ABfcf/HaPsnxS/wCgv4O/8F9x/wDHaAPQaK8++yfFL/oL+Dv/AAX3H/x2j7J8Uv8AoL+Dv/Bfcf8Ax2gD0GivPvsnxS/6C/g7/wAF9x/8dqO4g+KUMEsp1bwcdilsf2fcc4Gf+etAHotFc98PNaufEfgbQtZvliS6vrOO4lWIEIGZQTgEk4/GuhoAKKKKACiiigAooooAKKKKAOD1T/kuHh//ALAV9/6Ot67yuE1RT/wu3w+3b+w77/0dbV3dABRRRQAUUUUAFFFFAHFfGr/kkni7/sGT/wDoJrrtP/48Lb/rmv8AIVyXxq/5JJ4u/wCwZP8A+gmut0//AI8Lb/rmv8hQBPRRRQAUUUUAFFFFABXnPgr/AJLJ8Sv+uel/+iZK9GrznwV/yWT4lf8AXPS//RMlAHo1FFFABRRRQAUUUUAFcH8Rv+Rs+Hf/AGGX/wDSSeu8rhPiKCfFfw8I7ay//pJcUAd3RRRQAUUUUAFFFFABVfUf+Qfdf9cm/kasVX1DmwuR/wBMm/kaAOT+Cv8AySTwj/2DIP8A0AV2lcX8Fhj4S+EQf+gZB/6AK7SgAooooAKKKKACiiigAr4P+KPxQ8b6X8SfFFlYeJ9TgtLfUriKKJJcKiCQgKB2AFfeFfm58ZP+Ss+MP+wtc/8AoxqAHP8AFHxu+pQ6g/ibUTewxPBHMZPmVGKllB9CVX8hVlvi/wDEFhg+LdW/CbFcHRQB+pOkSPLpNlJKxaR4EZmPclRk1ynjbX9SfWrTwp4VdIdcvYHuJb2RBImn24OPNKE/Oxb5VXpnJPA55aPx94y02Xw5pMvga0a41ONktMa2uH8uLexP7r5flFXPhdc6nefEfx5P4i09dN1UrYBbVbjz1SARNt2vgBgW8w9OpI7UAXj8H/C14BL4iTUNfvsfNdajeyu55zgBWCqOegAFVNV0nUvhrbSa14evdR1Lw5arvvtFupTO0cQxmS3kc7lKAFihJBGcY4r1CmT+WYJBNjytp356YxzQBHY3cF/ZQXdnKsttPGssUinhlYZBH4GvMtb0WPxN8Zb7T9Qv9WisrbQ7eeOGz1Ca2Xe08wLERsMnAA/CtX4CGY/CPw99o38RyCLeP+WIlfyse3l7Me2KLH/kvGsf9i9af+lE9ADLv4R+HLy2ltru68Qz28qlJIpdbumV1PUEF8EVKvwr0JVAW/8AEoA4AGu3fH/kSu9ooA83+CPmxWHiyzku7y6isfEV3awNdXDzukSCPau5yTgfXvXVeOPEkXhTw7PqclvJdzbkhtrWIgPcTOwVI1z3JI+gya8k8I+I/E2gP8Qp9H8L2+q6Zb+Ib+4luX1NbdlKhSyhCjE4ABznnNTSeJdc8U+KPhlf+I/D0Ok+HLq7N1byC/FwJZ3tXa33AIpVsk49ST6UAdXb/DmTxFAbr4j6ldatcTfMdOhme3srYdRGEQjzCp/jcknaDxTpPhba6NGJvh/qV74bvUbcqLM9xaSnjIlgdiDkDGRgjg54r0aigDmfAPiZ/E2kzveWjWGrWM7Wd/aE58qZcZwe6kEMD3BrpjgcmvPvDXlD40eNfsf3DYaebrGcefiXGffy/L6dsV03jdrxfBevtpnmG/Gn3Bt/LGW8zy227R65xigDjLVtS+Jt3cXMGp3uk+DLeZ7eEWT+XPqjI2Gk80cpFkMoC4ZuSSOBVhfgx4LhYzadY3mnX+OL60v50uAcfe37zk898571u/CwW4+GnhYWW37P/Zlvt29P9Wuf1zXU0AcB4c1bVfDnii28J+KLx9SS9jkl0rVXRUeYJy0EoHWRVwd4ADD0INd/Xnnxi4XwYYd320eJLLyNud2Mt5n4eX5mfbNeh0AFFFFABRRRQB5f8cfi1ZfDTSYljiW81y7BNtasSFCg4LuR0UenUn8SPj7xN8Y/HHiHVba/u9bkhktJTNbJbKIkhYhlyoA67XYZJJwetaP7TmpXOofGjXlunJS1MdvCuThUCKcDPuSeO5NeV0AfVPwY/aQvLrVrfR/iA0LRTtsi1KOMIVcngSKOMdsgDHGe5r6rHNflYPav0l+EOo3OrfDDwve3zl7mXT4jI5JJYhcZJPJJxkmgDmfFNjfeIvjF/Yi+Itd0nT4dBS8CaZciHdKbh0JbKnPGPyrQ/wCFYS/9D947/wDBmn/xulj/AOTg5/8AsV4//St69DoA87/4VjL/AND746/8GSf/ABuj4MS3v2PxXY6hqd9qf9na/cWcE99L5kvlLHEQC2B3JPTvXoleD6D4o8ReGG+JN9pfhm31TSbTXL27uLl9SFuy7YoyyhCjE4VQc55zigD23VtQtdJ0261DUZkgs7aMyyyucBVAyTXxZ8Sv2j/E/iC8nt/DEh0TSOVXYFaeQZ+8zkfLnHRfUjJr0P8AaG8XeLdR+D4e/wDDltpOl6jLBmePUhcM6MC6rt8tcZwDnPbHevkagD1LwB8cfGXg42dvHf8A2/SYAifYblQV8tRjarYyvHp+INfa/wAMvG2n+P8Awla63po8vzMpPblgzQSDqhx+BB7gg8dK/Navp/8AYfvJxq3imyDn7K0EMxXH8YZgD+RNAH1rRRRQAUUUUAFFFFABX5ufGM5+LHjDH/QWuf8A0a1fpHWDdeDfDF5cy3N34c0We4lYvJLLYxMzsepJK5J96APzJor9Mf8AhBfCP/QraD/4Lof/AImj/hBfCP8A0K2g/wDgvh/+JoA5LXTnx38I/cXn/pEa2PGuiana67a+LvC0IudWtYGtrrTzIIxqFuTkJvIIV1b5lPfJB4NU/G6hPir8MVQBVE2oAADAA+yNXolAHAW/xd8HgGPV9RfQ75MeZZ6rC9tKh9MMMN9VJFZuqeILv4k2kuieEIL+20O7TZea/NCYUERxujt0ddzsw3LuwAvXnivTniRyC6KxHqM08DHSgCtptlbabp9tY2MSw2ttEsMUa9ERRgD8hXnN1relaL8c9Tk1nU7HT0k8P2qo11cJEGIuJ8gFiM16fWTqvhrQ9YuFuNX0XTL6dV2CS6tY5WC5JwCwJxyePegCl/wnnhD/AKGrQP8AwYw//FUn/CeeEP8AoatA/wDBjD/8VTv+EF8I/wDQraD/AOC+H/4mj/hBfCX/AEK2g/8Agvh/+JoA878DXMF54B+K1zaTRz28usaq8csTBldTEpBBHBB9a3tF8NJ4q+CHhSw+0NaXSaZYXNpdooZraeOJGSQA9cEcjuCR3rofEml6fpHgDxBbaVY2tjbmxuXMVtCsS7jEcnCgDPApPhX/AMkx8I/9gi0/9EpQBg2fxKi0QLY/EW1l0DUU+T7U6M9ldY48yOZRhQcZ2vtI3Ac067+Kml3+bXwNbT+KdUbAWKzUrAnq0k5GxAPqTyBjmvQ2VXXDgMPQjNCIqDCKFHoBigDl/h94Zm8OaXctqd0t9reozteahdBcCSUgDao7IoAUD0GcDNdQQCCDyDS0UAeXWct58LJZrKWwvdQ8FSzST21zaRmWTSgzbmieNRuaIEswcZIHBHQ1ov8AGLwKYUa112O8nf7lraQySzscfd8tV3A9uQMd8V6BTFijVtyoob1A5oA4Dw9p2qeKvFNp4r8R2M2l2dhG6aVpU7AyKz8NcygfdcphQnO3nvXoVFFABRRRQAUUUUAfLf7Wnws1DUr4eM9AtmuQsKxahBGC0g28LKB3GMA46YB9SPlAgg88V+qdcnq3w48Gaveveal4Y0i4unJLytbLuYkkknA5OSeTQB8H/Cj4c6v8RPEUNjp0Lx2KMGu71lPlwp357sey9/pkj9E9MsbfTNNtLCyTy7W1hSCJMk7UUBVGT7AUadYWemWiWmm2lvaWqZ2QwRiNFycnCgYHNWaAPOt6R/tBTl2VQfC8fJOP+Xt69A+0wf8APaP/AL6FYXiPwT4Z8TXkd3r+iWOoXMcflJLPEGZUyTtz6ZJP41lf8Km8A/8AQp6R/wB+BQB2X2mD/ntH/wB9CvF7Ehvhx8bCpBB1HVuR/wBeqV2v/CpvAP8A0KWkf9+BUXjHw9pHhr4R+MbLQNOttPtH0y8laK3TapcwMC2PXAA/CgB194WtvGnwctdAvHaOO80u3VZF6o4RWVvwYA4r4J8b+DNd8Fau+neIbGS2mGSj9Y5V/vIw4I/ycV+jHgv/AJE7Qv8Arwg/9FrV/UtPstTtWttSs7e8tnxuiuIlkQ4ORkEEdQPyoA/MLR9LvtZ1GCw0q0mu7ydgkcMSlmYmvvD9nT4bSfDzwY41NQNc1JlmvFDbhEBkJGCODgEkkd2PJAFejaRoWkaN5n9j6XYWHmYL/ZbdIt2OmdoGeprRoAKKKKACiiigAooooAKKKKACiiigDzzx1/yVf4Z/9d9Q/wDSRq9Drzzx1/yVf4Zf9d9Q/wDSRq9DoAKKKKACiiigAooJABJ6CvOP+F3fDvt4kiI9RbTH/wBkoA6zxz/yJXiD/sH3H/otqpfCv/kmPhH/ALBFp/6JSuM8V/GTwDe+F9YtbbxBHJPPZzRRoLaYbmZCAOU9TVT4ffGDwJpngLw3YX2vxw3drpttBNGbeYlHWJQwyExwQaAPZqK84/4Xd8PP+hkj/wDAaf8A+IpB8b/h2eniWI9uLaf/AOIoA9Iorzj/AIXd8O/+hkj/APAaf/4ij/hd3w7/AOhkj/8AAaf/AOIoA9Horzj/AIXd8O/+hkj/APAWf/4it/wj4+8MeMLm4t/Dmqx3s9ugklQRuhVScA/Mozz6UAdRRRRQAUUVynifx7o3hzWotJvU1KfUJLf7UIbKwmuSItxXcdinAyCKAOrorgv+FpaL/wBAzxR/4Ibv/wCN0v8AwtLRf+gZ4o/8EN3/APG6AO8org/+FpaL/wBAzxP/AOCG7/8AjdQXfxc8OWYhN3a+IYBNIsMfm6LdLvkb7qjKcsewHJoA9Dorg/8AhaOi/wDQN8T/APghu/8A43R/wtHRf+gb4n/8EN3/APG6AO8org/+Fo6L/wBA3xP/AOCG7/8AjdR3PxZ8P2ttLcXVl4jht4lLySyaJdKqKBkkkpgADvQB6BXL/FT/AJJj4u/7BF3/AOiXrKT4qaG6K6ad4mZGAKsuhXZBHqP3dYfjz4g6dq/gfxDptjpXiZ7u80+4t4VOh3ShneNlUZKYHJFAHoHgv/kTtC/68IP/AEWtbNeY+G/iRpVj4d0q0udK8TrPb2kUUijQro4ZUAIzs9RWkPilov8A0DPFH/ghu/8A43QB3lFYvhLxNpvivTJL7SGnMMU720izwPC6SIcMpVgCCK2qACiiigAooooAKKKKACiiigAooooA888df8lX+GX/AF31H/0kavQ6878df8lY+GX/AF31H/0kavRKACiiigAooooAZN/qn/3TXC/Ab/kj3hX/AK8x/M13c3+pf/dNcH8Bf+SPeFf+vMf+hGgDvqKKKACuC+DP/Ivax/2HtT/9KpK72uC+DP8AyL2sf9h7U/8A0qkoA72iiigArz60/wCS/al/2Ldv/wClM1eg159af8l+1L/sW7f/ANKZqAPQaKKKACvOv+biD/2Kv/t3Xotedf8ANxB/7FX/ANu6APRaKKKACvO/jP8A6nwX/wBjTp3/AKGa9Erzv4z/AOo8F/8AY06d/wChmgD0SiiigArkvi9/ySvxf/2Cbr/0U1dbXJfF7/klfi//ALBN1/6KagDe8P8A/IB03/r2j/8AQRV+qHh//kA6b/17R/8AoIq/QAUUUUAeefBf/jy8Xf8AYz6l/wCja9Drzz4L/wDHl4v/AOxn1L/0bXodABRRRQAUUUUAFFFFABRRRQAVleJ/EWk+F9Im1PXr6GysouskrY3HBIVR1LHHAHJrVr4l/a/8WXeq/EX/AIR8O66fpEaYixgNK6hy/v8AKyj8D+IB1PjH9pDQ7zxl4e1LS9Dvri30eSd900qxNL5kTR4Aw2ByDk/TAr2z4Y/GDwt8Qma30u4ktdSXk2N3tSVhzkrgkMOO3Tvivzwq/oeq3mh6vZ6npkzQXtpIJYpF6qwoA/UWisnwjq41/wAK6PrATy/t9pFc7MY270DY7+ta1ABSEhQSSABySaWvPfizI+q3XhzwbHNLCniC6cXbxkqxtIU8yZAwIwW+RPox60ANuPiNPq7TxeA/Dd94kSNjE16JUtbMsCQwWZ/vkEH7oI9+a5/4e+Jrr4e+EdF0Dx7oN9o0VqgtxqgZLizJJ+Xe6EmPJbHzDHv1x6/aW8NpbRW1rEkNvEoSONFCqqjgAAdBS3EMVzBJDcRpLDIpV43UMrA9QQeooAerBlDKQVIyCDkEVzfjvxZF4RsdPnk0+91Ga/vUsILe02b2kdWYffZRj5D39KwPhUX0bU/E3gxpZZbfQ54pLF5GLFbSdS8ceSSTsKuoyegHSj4xf8fPgD/sabT/ANFzUAT/APCd61/0TvxR/wB9Wn/x6ua8Ba54i8OaXf2134A8RSvcald3qmJ7bASWZnUHMo5AYZ969iooA4vwz47OseK38P33h7VtG1AWRv1F75RDxCRU4KO3OW/Q12ledP8A8nEw/wDYqv8A+laV3eq38Gl6XeahePstrSF55WwTtRVLE8ewNAGN4u8ZaP4VFvHqU0sl7dZFrY2sTTXFwR2SNeT6ZOB715xH4n1O0+I9x4s1DwV4nttFn0mKx3/ZklkjKyySb3jRywXawzxkYORXVfCTSnuNHTxbrSLL4h11ftTyuATbQPzHbxnGVjVdvGeWyTmvQKAMzw7r2l+JNLj1HQ72K9s5CQJIz0I6qQeVI7ggEVp15r4lto/Bnj7RNf00Lb6drd0ul6pbRrtjeWTcYbjAH+s3/IWOchh6Zr0qgDzq0+JV3qH2iTSfBPiK/tIriW2FxCbYI7RuyMRulBxuU9RXO/2x4j/4Wl/wk3/CA+Ivsf8AY39m+XvtvM8zz/Mz/rcbccdc5rq/gp/yJc//AGFtS/8ASyWu8oA861H4j6jpthc31/4B8TQ2lrE000pa1IRFGWbibPABNd7p15FqGn217bEmC4iWaMkYJVgCOPoa5/4p/wDJMfF3/YIu/wD0S9XvBH/Il6B/2D7f/wBFrQB558Q/j14b8CeKrnQdV0/VpruBUdnt44yhDKGGCXB6H0rzfxv+0Z4T1+LRVt9M1pTY6tbX7eZFGMrE2SBhzzjpXmH7WH/JbdX/AOuFv/6JWvH6APtI/tVeDe2k6/8A9+ov/jlexeAfFVn428J2PiDTYbiG0u9+xJwA42uyHOCR1U96/Muv0B/Zf/5Id4b+k/8A6PkoA9SdlRGd2CqoySTgAV86fGj4/wDhVdE1zw1oyT6vcXdrLaNcwMot03oVJDfxYyOgwfWtr9rnxbdeHfh3Dp2nu8U+szG3kkUdIQuXGc8E5UfQtXw7QB9tfDn9o/wnrMlpperwT6HNtEaS3Dq8BwBjLjG3PuMe9e8oyuoZGDKwyCDkEV+Vlfcn7JHi668R/DqTT9Qd5bjRphbJIw6wlcxjOeSMMPoFoA9wrivEHj+3s9Ym0XQNLv8AxDrkKgzW1ioEdsSMr50rEImfTJPHTpm18U9cuvD3gXU73TF3aiwS2tATjE0rrEh544ZweeOK0PBnhy18K+HbTSrNml8pSZZ5CS88rHLyOSSSWYk9e+OlAHmXgrWPEvge21qTxX4L1CGwvtTudTa50+4jvfs6yvuIdFIbC/3lB4ycDFetaHq9hr2k2up6PdR3dhcpvimjPDD+YPYg8gjBq9Xm9pGnhH4wrY2pMemeK7aW5EAztS9g2l2UdF3xsCeOSo65oA9IooooAKKKKACiiigAooooAK+Jv2wPCd1pXxEHiAIzWGsRJiTIIWWNQjL7fKFP4n0NfbNZniPQdL8S6TNpmu2MF7ZSjDRyrnBwRuB6qwzwRyO1AH5fVf0LSbzXdZstL0yEzXt3KsMMYIG5icDk9PrX1xrH7KXh25vnl0vXdSsrZuRBJGs2057NwcdOuT7mvTfhp8I/Cvw9zNo9o8+osMNfXZEkwHPCnACjkj5QM8ZzQB1fhPSF0DwvpGjo/mLYWkVsH/vbEC5/StWiigArzr4tK2kah4X8ZeXJJb6Ddut6EG7ZaTp5ckm0Ak7TsbjsG/D0WmyIsiMkihkYEMrDII9DQAkMiTRJLE6vG6hlZTkMDyCKV3WNGd2CooyWJwAPWvPF+HupaDM58A+JptFspHZ20y6txeWiEkk+WpKtGMknCtjPbtSSfD3VPEEir4+8UTaxp6sHGmWdsLO2kIwR5gBZ5BkA4LYz27UAHwpJ1zWfFXjNFdLLWbiKCw3jb5ltbqUWXBGRuZpCM9sfivxi/wCPjwB/2NNp/wCi5q9ChjSGJIoUWONFCqijAUDoAOwrjfin4c1nxDYaG/hyXT49R0vVYdRT7eXETBEkXadgJ6uPTvzQB2tFeb/8Xe/6kH/yco/4u9/1IP8A5OUAOf8A5OJh/wCxVk/9K0rtfEmmLrfh3VNKd2jS+tZbUuvVQ6Fcj864jwn4b8YH4jP4n8YS6BhdJbTY4tLM3eZZNzeYPYjg+nFekUAcT8HdWXUfAOm2sgEeo6Sg0u+g7wzwgIyn64DD2YV21cZ4l8EyXetf294Z1ebQtdKhJpY4xLBdqOgniOA5A4DAhgD16YyxZ/Fa6JtrjVvCNhAQR9ttbWeWcccERuwTJ+pA96AF+Jcq6z4r8H+FrRg15/aEes3OOfJtrclgx9N0m1Rxz83TFejVzng3wlaeGYrmQXFzqGqXj+ZeajdsGmnbsMgYVBkhUGAB+JPR0AcH8FP+RLn/AOwtqP8A6WS13leTaFoHxN8NW91YaLJ4Nl09r25uYWuzdebiWZ5MNtAGRu7Vpf8AF3f+pC/8nKAN/wCKn/JMfF3/AGCLv/0S9XvBH/Il6B/2D7f/ANFrXBeIdK+LGu6BqWk3L+Bo4L+2ktZHjN3uVXUqSMgjODXo/h6xfS/D+mWErq8lraxQMy9GKoFJHtxQB8N/tYf8lt1f/rjb/wDola8fr6/+NHwC8R+O/iHqOv6bqmkwWlykSpHcNIHXZGqnO1COoPeuG/4ZS8X/APQa0D/v5N/8boA+ea/QH9l//kh3hv6XH/o+SvBP+GUvF/8A0GtA/wC/k3/xuvpr4OeFLzwR8OtK8P6lPbz3dp5u+S3JKHdK7jGQD0YdqAOC/a38IXPiP4dR6jp6NJcaLK1y6A9YSuJDjuRhT9Aa+HK/VNlDKVYAqRgg9DXiHjv9m3wj4kvnvtLkuNCuZGBdLVVaA9c4jONp6dCBx0oA+HK+5f2SvCFz4b+HD6hqEbR3Osyi6VC2cQhcRnHYnLH6EUngT9m7wh4av477U3uNduYySiXaqIB6Exj7xHPUke3Fe3ABQAoAA4AHagDk/itot5r3gPUrTS8f2jH5d3aqejSwyLKi8+pQD8a1PB/iGz8VeHLHWdOLCC5TJRwQ0bg4ZGB6FWBB+lbNcLrnw/3azc634S1i68OazdEG5aBFlt7ojoZYW+Ut/tDB5POeaAO6rzZHTxX8Z4bi1y+n+ErWaF5lBAN7cABo84w22NcnHQsKlm8H+MdXAt/EHjpl048SxaRp62cso9DKWdlHH8ODgkV2fh3RNO8O6NbaVo1qlrY267Y41/Uknkknkk8k0AaNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeBftE/HGfwLep4f8MRwS620YluJ5l3JbKw+UBe7kc88AY4OeAD32ivhLw/+0j8QtO1KKfU9QttWtQRvtp7WKIMO+GjVSD78j2NfaHgfxNY+MfCmna9pe4Wt7HvCN96NgSGQ+4YEfhQBu0Vi+MPE2leD9AuNZ1+5NtYQFVdwhc5ZgoAUZJ5Pb61j638R9A0q18PzeZPeHXgHsIrZAXlQpv34YjAwR1OecYoA7KiuQ8N/EPQNft9Uu7W4NvpthP9na+uykUErbmU7GLcjK9wOoxmt+61vSrOG2lu9TsYIrnHkPLcIolz02kn5vwoA0KKwtK8X6Bqo1RrHVbZ10ud7a8LN5YhdcbslsZXkfMMr78Grj67pKabHqD6pYLYSsFS5Nwgic+gbOCeD3oA0aK5XTvHeiXvw+HjMyy2+ieQ9wXnTDhVJU/KCeSRgAdcirGheMdI1bSNO1B5xpyahn7NDfyJFLLzj5V3HOfY96AOioqhNrOmQXQtZ9Sso7kkgQvOockDcRgnPA5+lRT+ItEgsre9n1jTY7O4JEM73SCOUjrtYnB/CgDUorBi8V6ZJ4lvNE8xluLWyTUJJmwIfJdmAIbP+yT6YrV06/s9Sthc6dd293bsSBLbyLIhI68g4oAs0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXwb+1bot7pnxi1S8ukk+zakkVxbSt0dRGqMM+qspGOwx6ivvKsDxp4P0LxrpP9neJdPivbcHchbKvE395GGCp+h575oA/Mqvvz9l7RrzRvg5pKahG0Ut08l2kbDBEbtlCfqAG+hFM8O/s9/D/AETU1vl02e+kRt0cd7OZI0P+7gBv+BZr1sDAwOlAHAfE/wAGar4z1Lw7Dbahb2OkafcNe3BaMSyPMq4iwjKVKjLk5PcccVyPhP4R6tpt34Lh1qXR9R0/w1eX/lu4ZpZbWVD5AIKY3q5JIzgYGCTXttFAHg0nwW1KLwto1tZyaSuoafql3eyQhmjguY5S4QM4jJDorAA7CByOlT6b8JtZ0Y2M1lZeGNQC6W+mvYarLNNDbAzyShonMZLghwCpVM44IHA9yooA8M1X4O6rc2vim0s30SCK/wBbXWbSYBg7gFT9mmATiMFSQQW5OcClsPhPrVh/Yl3BbaDJPY6ld3smnXV1NPbSCeFE37zEPnVkLAbAPmPIPNe5UUAeW6b8OtRg/Z/fwLdSafLqhsZbcSbmaASM7MjZK7sAlTnbkEcVzPi74LX2o3tvJYrpM9m+lQafNZzTPbLC8ZLb42SNsqWJYjCnPOea94ooA8T1r4O3Wq+I73UrqPRbj7Rr+n6iWnDPI1pDGFliYlDktg/Lkqc8kVQ1D4QeJG0GLSrKfQ/sIvdRma2LvEqxzsDFtdYiw24+aMbVPHJxXvdFAHgk3wX1260CbT59T0+J20DT9MDIzurTW03mEMCozGwAGevtxg998JvCF54StdVF/DZQS31ws7JaXUk6lgoUsSyJgnA4C9uSa72igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmf43fHvxR4E+Il/oOkWGizWcEcTq91DK0hLIGOSsijqfSvpivgv9rD/ktur/8AXG3/APRK0AdB/wANV+OP+gV4b/8AAef/AOPV9M/BHxhqHjv4d2GvavDaw3k8kqMlqrLGAshUYDMx6D1r85q+9f2T/wDkiWj/APXa5/8ARzUAepazqthommzahrF5BZWMOPMnncIi5IAyT6kgfjWfrHi7QtHtNOub/UoUh1EgWZjBlM+V3AoEBJGOcjjFch8ZvDOveMpPD+jaXa2j6OtybzUJbxv3LeWP3cTIrB2DFiTgY+UVxPhX4ceJHu/h5a+KdMaWDw1dX9rLdpeKBJaiM/ZpAFfcAWIXGNwC/MMUAe1aD4m0jX7nUINHvUu3sJPKuDGrbVfJGAxGG5VgdpOMVsV83r8LfE1j4G0qzsrCb5NXu7jUdNS8UtcwsziBgWkCHaCDtLDJOTyKu2/gXxNBFpH9taHqviTT4NLa1gspdYjhms5/Pdlkdg4U/uzGodGZlC4wcZoA96sr+zvzcCxu7e5NtM1vOIZA/lSgAlGwflYZGQeeRVmvni++G3ie2s/GtpoumzQyX2uDUI511ABL6yJQm2AL5VshiSwAI4yRUln4E8TQaboEN1o+q6hotrql3Pc6LPqEEb7JIkELArJs8tJBIdm8kbs47UAe56BrOn+IdHttV0a5W6sLkFoplBAYAkHggHqDWhXkfhzwp4i079m5vDP2V4PEi6bcQpAk6BhKzOVAkDbR1HO6uQn+FviO2udUn02zv1lin0i604nVScSrj7a+GlwW4GS3X+HNAH0TLIsUbySHaiAsx9AKp6Jq1jrmk2up6TcLc2NynmQyqCA6+uCAa8L1HwX41uPiq2sxaS9vbjVJt1zbXcQimsmjYKWDSeYWJxlcBR/CD1GTffDPxo/hvwjZz2d5La2ejG0lsrO8hWW0u/MZvOXdIqE7SoDBiRt6c0AfTFFUtDjuIdF0+K+aRrtLeNZmkYMxcKNxJHBOc8irtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeOfEf4BaD488WXWv6jquqW1zOiI0cBj2AIoUYypPavY6KAPnX/AIZR8K/9B3W/zi/+Ir2P4ceDrPwH4TtdA064uLm2t3d1knxvO9ixzgAd66eigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autosomal dominant trait. Features of autosomal dominant inheritance seen here include: affected individual in each generation;&nbsp;lack of gender bias; &sim;50 percent affection rate among siblings of affected subjects.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_23_4479=[""].join("\n");
var outline_f4_23_4479=null;
